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                                                    ABSTRACT 
OBJECTIVE 
 To compare the effect of Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile in various patient population 
METHODOLOGY  
                   The study was conducted in outpatient department of General 
Medicine, Nephrology, Madurai Medical College, Madurai, between 
February 2013 to August 2014. 120 patients with Dyslipidemia were 
selected based on measurement of lipid profile. Out of 120 patients, 60 
patients were treated with atorvastatin 10 mg/day orally and the remaining 
60 patients were treated with atorvastatin 10mg and vitamin D3 1000IU/day 
orally. In atorvastatin group, 30 were Hypertensive and 30 had chronic 
kidney disease (CKD). In atorvastatin vitamin D3 group 30 were 
Hypertensive and 30 had CKD.The plasma lipid profile was assessed at the 
beginning, third month and at the end of sixth month. The results were 
tabulated and analyzed statistically 
 RESULTS  
  All the patients were followed up till the end of the study. There were no 
dropouts. At the end of sixth month the mean total cholesterol was 
significantly reduced in atorvastatin vitamin D3 group than in atorvastatin 
group with ‘p’ value <0.001. The mean Low Density Lipoproteins, 
Triglycerides, and very Low Density Lipoproteins were significantly 
reduced in atorvastatin vitamin D3 group than in atorvastatin group with ‘p’ 
value <0.001. The mean High Density Lipoproteins in atorvastatin vitamin 
D3 group was- 45.32 and in atorvastatin group was-44.28 with ‘p’ value 
<0.001. 
CONCLUSION 
       Fasting plasma lipid profile improved significantly in both groups. 
However the improvement was very high in the atorvastatin vitamin D3 
group. The Atorvastatin and vitamin D3 treated group showed  good 
response compared to atorvastatin treated group 
Key words- Atorvastatin, Dyslipidemia, lipid profile, vitamin D3 
                                           INTRODUCTION  
          Dyslipidaemia and atherosclerosis are closely linked to cardiovascular 
diseases like hypertension, coronary artery disease1. Dyslipidaemia is an 
independent risk factor for cardiovascular diseases (CVD). In India the most 
common cause of morbidity and mortality includes CVD2. Dyslipidaemia is 
a disorder of lipoprotein metabolism. This includes either lipoprotein 
overproduction or deficiency3. Dyslipidaemia can be diagnosed by doing 
plasma lipid profile. This is manifested by elevation of the total cholesterol, 
the low-density lipoprotein (LDL) cholesterol and the triglyceride 
concentrations, and a reduction in the high-density lipoprotein (HDL) 
cholesterol concentration in the blood3. A large proportion of individuals in 
the society have dyslipidaemia, often associated with modifiable risk 
factors. 
   The global prevalence of hypercholesterolemia among adults in the year 
2008 was 39% (37% males-37% and females- 37%). The most common 
lipid abnormalities observed in Tamilnadu as per the ICMR-INDIAB study  
are hypercholesterolemia-18.3%, high LDL-15.8%, low HDL-72.3%4.                    
The risk factors for dyslipidaemia include diabetes, hypertension, chronic 
kidney disease, physical inactivity. The prevalence of dyslipidaemia in India 
is increasing, that calls for urgent lifestyle modification strategies. This is 
aimed to prevent and manage this important cardiovascular risk factors. 
   Vitamin D deficiency affects more than one billion population 
worldwide5. This pandemic of vitamin D deficiency can mainly be 
attributed to lifestyle changes (for example reduced physical activity, fast 
food) and environmental factors( air pollution due to various causes) .This 
result in inadequate  exposure to sunlight. Ultraviolet –B (UVB) rays in the 
sunlight induce vitamin D synthesis in the skin. 
     The increasing prevalence of vitamin D deficiency is an important health 
problem in the community. Vitamin D deficiency is an independent risk 
factor for mortality in general population6.  Various research supporting the  
role of vitamin D against  many diseases including  heart disease, 
hypertension, dyslipidaemia, type 2 diabetes ,autoimmune diseases, 
tuberculosis, cancer and mental illness. It is also observed that there is a 
strong correlation between low vitamin D level and fibromyalgia7. Many 
physicians have suggested oral supplementation of vitamin D -1000 
IU/day8. 
   Adequate vitamin D levels are necessary for good vascular health9. 
Vitamin D deficiency is associated increased incidence of CVD10. Seasonal 
variation in vitamin D levels - deficiency in winter leads to peripheral 
insulin resistance in type 2 diabetes mellitus patients which in turn alters the 
lipid profile contributing to metabolic syndrome11. Serum levels of vitamin 
D are inversely correlated with very low density lipoprotein and triglyceride 
levels. Low serum 25 (OH) vitamin D levels are associated with reversible 
myalgia in statin treated patients. Normalization of low serum 25 (OH) 
vitamin D by oral vitamin D supplementation reverses myalgia, which 
otherwise might cause satin intolerance. 
     Atorvastatin is the most effective drug for treating Dyslipidaemia. 
Atorvastatin acts by inhibiting HMG-CoA reductase enzyme. This enzyme 
involved in rate limiting step in biosynthesis of cholesterol in the body. 
Atorvastatin is effective in  reducing high LDL-C levels in patients with 
dyslipidaemia. It is also effective in reducing triglyceride levels. 
     There is a strong  relationship between elevated  levels of plasma 
cholesterol and atherosclerotic vascular disease. By reducing  the  total 
cholesterol and LDL cholesterol to below critical levels, there is a marked 
reduction in cardiovascular mortality. 
    Hence  this  clinical study was undertaken to compare efficacy  of the 
fixed dose combination of Atorvastatin with vitamin D and Atorvastatin 
alone on lipid profile  in patients with chronic kidney disease and 
hypertension. 
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To compare the effect of Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile in various patient population. 
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REVIEW OF LITERATURE 
        Hypercholesterolemia is defined as high levels of cholesterol in the 
blood which is by itself not a disease but a metabolic derangement that can 
be secondary to many diseases and can affect any system of body, 
particularly cardio vascular system. There are 2 types of 
hypercholesterolemia-primary & secondary hypercholesterolemia. 
Dyslipidaemia includes Hyperlipidaemia (hypercholesterolemia) and low 
levels of HDL-C. Hypercholesterolemia is a leading etiological factor for 
atherosclerosis and atherosclerosis induced conditions like ischemic heart 
disease, ischemic cerebrovascular disease, and peripheral vascular disease12. 
    The prevalence of dyslipidaemia among adults -37.5% in our country.3 
This prevalence depends on various factors such as socioeconomic status, 
area of residence, age, diet, physical activity and genetic factors. 
LIPOPROTEIN METABOLISM 
    Lipoproteins are macromolecular substances formed by the combination 
of proteins with lipids .They are spherical complexes13. Triglycerides, 
Phospholipids, free cholesterol and Esterified cholesterol forms the lipid 
content. The protein part is called as apoprotein or apolipoproteins. It may 
function as ligand or as cofactor which regulates lipoprotein metabolism. 
The protein components provide the structural stability to lipoproteins.   
    Hydrophobic lipids (Triglycerides and cholesteryl esters) form the core of 
lipoproteins, which is surrounded by hydrophilic lipids (phospholipids, 
unesterified cholesterol) and proteins. Lipids are transported by lipoproteins. 
Lipoproteins play an important role in the absorption of fatty acids, 
cholesterol and fat soluble vitamins. The amount of lipid and protein per 
particle determines the density of the lipoproteins. 
 Chylomicrons 
     Chylomicrons are synthesized from the dietary triglycerides and 
cholesterol absorbed from the small intestinal epithelial cells. After 
absorption from the enterocytes fat-soluble vitamins are incorporated into 
chylomicron molecules. 
      Chylomicrons are the largest plasma lipoproteins and float to the top of 
plasma when allowed to stand undisturbed for 12 hours. The buoyancy of 
Chylomicrons are due to  their high fat content (98-99%), of which nearly 
85% is from fatty acids of dietary triglycerides. In chylomicrons, ratio of 
triglycerides to cholesterol is 10 or greater. In individuals with normal lipid 
profile, after a fat-containing meal, chylomicrons are found in plasma for 3-
6 hours. Chylomicrons are not found in plasma after 10- 12 hours of fasting. 
Niemann-Pick C1–Like 1 protein (NPC1L1) mediates absorption of 
Intestinal cholesterol and plant sterol, which appears to be the target of 
ezetimibe, a cholesterol absorption inhibitor14. Plant sterols, unlike 
cholesterol, are not normally esterified and incorporated into chylomicrons. 
ABCG5 and ABCG8 are located on the apical plasma membrane of 
intestinal epithelial cells and are called ATP-binding cassette (ABC) half-
transporters, and they transport plant sterols back into the intestinal lumen, 
preventing their assimilation into the body. Sitosterolemia, a disorder with 
mutations in either of the genes that encode ABCG5 and ABCG815. Leading 
to abnormal absorption large amounts of plant sterols, failure to excrete 
dietary sterols into the bile, and thus leads to accumulation of  plant sterols 
in the blood and tissues leading to subcutaneous and tendon xanthomas and 
also substantially increases the  risk of premature CHD. This is an 
autosomal recessive disease. 
      Triglyceride synthesis is regulated by diacylglycerol transferase in many 
tissues. In the endoplasmic reticulum, triglycerides are transferred by 
microsomal triglyceride transfer protein (MTP) to the site where apoB-48 is 
available to form chylomicrons. 
    The apolipoproteins of chylomicrons derived from enterocytes. These 
include apoB-48, apoA-I, and apoA-IV. Others acquired from HDL apoE 
and apoC-I, C-II, and C-III. From the enterocytes Chylomicrons have been 
excreted into the lymph and enter the systemic circulation. The apoB-48 of 
chylomicrons is one of the two forms of apoB present in lipoproteins. 
ApoB-48, synthesized by enterocytes. In the liver Apoprotein B-100 is 
synthesized. Apo B-100  is  incorporated into VLDL and intermediate-
density lipoproteins (IDL) and LDL, which are products of VLDL 
catabolism. The apparent molecular weight of apoB-48 is 48% that of apoB-
100, which accounts for the name "apoB-48." The amino acid sequence of 
apoB-48 is identical to the first 2152 of the 4536 residues of apoB-100. An 
RNA-editing mechanism unique to the intestine accounts for the premature 
termination of the translation of the apoB-100 mRNA. ApoB-48 lacks the 
portion of the sequence of apoB-100. Apo B-48 is an important structural 
component of chylomicrons.  
     Dietary cholesterol is esterified by the type 2 isoenzyme of acyl 
coenzyme A:cholesterol acyl transferase (ACAT-2)16.  Type 2 isoenzyme is 
found in the intestine and in the hepatocytes. Here cellular free cholesterol is 
esterified before triglyceride-rich lipoproteins  like chylomicrons and VLDL 
are assembled. In the absorption of dietary cholesterol in the enterocytes is 
regulated by type 2 isoenzyme. Thus for reducing blood cholesterol levels 
this type 2 isoenzyme act as a therapeutic target. 
  Another  isoenzyme is  ACAT-1, which  is expressed in  
 Macrophages include  foam cells 
 adrenocortical cells 
 sebaceous glands.  
    Chylomicrons enter into the  systemic circulation through thoracic duct. 
The capillary endothelial surface contains lipoprotein lipase (LPL)17. 
Triglycerides of Chylomicrons are degraded by this enzyme. It is also called 
as triglyceride hydrolase. 
       These tissues include adipose tissue, skeletal and cardiac muscle, and 
breast tissue of lactating women. The triglycerides are hydrolyzed by LPL. 
The free fatty acids are released. These free fatty acids are taken up by the 
adjacent cells.  It will be used for energy production. The interaction of 
chylomicrons and LPL needs apoC-II as  a cofactor. The absence of 
functional LPL or functional apoC-II prevents the hydrolysis of triglycerides 
in chylomicrons and results in severe hypertriglyceridemia and pancreatitis 
during childhood or even infancy (chylomicronemia syndrome)18. 
Potentially atherogenic roles for LPL have been identified that affect the 
metabolism and uptake of atherogenic lipoproteins by the liver and the 
arterial wall and that impact the dyslipidaemia of insulin resistance . 
 
 
 
 
 
Figure -1  Fate of chylomicrons 
 
Chylomicrons are converted to chylomicron remnants by the hydrolysis of 
their triglycerides by LPL. Chylomicron remnants are rapidly cleared from 
the plasma by the liver. "Remnant receptors" include LDL receptor–related 
protein (LRP), LDL receptors, and perhaps other receptors. Free fatty acid 
(FFA) released by LPL is used by muscle tissue as an energy source or 
taken up and stored by adipose tissue.  
Chylomicron Remnants 
    From the chylomicron 90% of triglycerides are removed. This decreases 
the size of the chylomicron. Thus chylomicron remnants are formed from 
the chylomicron.  They are transported to liver through systemic circulation.  
Apo E content of the remnants interact with the heparin sulfate which is 
located on liver cells.  They are further degraded by the hepatic lipase. This 
decreases the triglyceride content. They are taken up by the hepatocytes via 
LRP receptors (LDL receptor related protein). This is known as LDL 
receptor mediated endocytosis.  LRP not only recognizes apo E but also 
interact with other ligands not related to lipid 19. 
    In plasma lipid metabolism, the LRP interact with apoE of remnants of 
chylomicrons and VLDL.  Mutation or Inherited absence of either HL or 
functional apoE   will reduce the clearance of remnant by the LDL receptor 
and the LRP. This result in elevated triglyceride content of the plasma leads 
to familial type III hyperlipoproteinemia or familial dysbetalipoproteinemia. 
       Within the lysosomes of liver cells  most of the remnants are 
hydrolyzed to glycerol, fatty acids and free cholesterol.  Some of the 
remnants of chylomicron are degraded to PL-rich lipoprotein termed as 
remnant remnants. The fate of remnant remnants is not well known. The 
catabolism of chylomicron is very rapid. The half life is 60 minutes. 
Very Low Density Lipoproteins (VLDL)  
      Major quantity of plasma  VLDL is synthesized by hepatic parenchymal 
cells.  Minor quantity is synthesized by mucosal cells of  small intestine. 
The diameter of VLDL particles are 40-100 nm. As compared to 
chylomicrons, VLDL has more density because it contains higher 
percentage of protein content.  It Is composed of lipids-95%, protein- 5%.  
The lipid components are  
 Triglyceride- 60% 
 Phospholipids- 15% 
 Cholesterol- 20% 
The protein components  are20  
 ApoB-100- major lipoprotein 
 ApoE - obtained from HDL 
 ApoC- obtained from HDL 
      From the liver  cells VLDL is secreted into  the circulation by reverse 
pinocytosis. The nascent VLDL  contains only apo B100. Apo E and apo C 
are obtained from the circulating HDL. VLDL is the carrier of endogenous 
triglycerides. They transport endogenous triglycerides from liver 
parenchymal cells to peripheral tissues like adipose tissue and skeletal 
muscles for energy needs. This is the main function of VLDL. 
      In adipose tissues and skeletal muscles, VLDL is hydrolyzed by 
lipoprotein lipase. Free fatty acids released due to hydrolysis, are taken up 
by these tissues for energy production. Hydrolysis of VLDL results in 
removal of triglyceride that reduces the diameter of particles and increases 
the density of VLDL. Thus VLDL remnants are formed. The VLDL 
remnants then release their apoproteins – apo E  and apo C, which are 
transferred back to circulating HDL and the VLDL remnants are 
transformed into Intermediate Density Lipoprotein ( IDL) then to Low 
Density Lipoprotein (LDL). This is known as lipoprotein cascade 
pathway.LDL thus produced retains apoprotein B 100, and contains more 
cholesterol and less triglycerides. 
Low Density Lipoproteins 
LDL is derived from the metabolism of VLDL. It is neither synthesized in 
the hepatocytes nor by the mucosal cells of intestine. The density of LDL is 
more compared to VLDL. The protein content of LDL is high compared to 
VLDL. The composition of  LDL includes lipids - 80% and protein -20%21. 
The lipid components are 
 Cholesterol- 50% 
 Phospholipid- 22% 
 Triglyceride- 8% 
The protein component 
 Apo B 100 
The plasma half life of LDL is about  36-48 hours. LDL transports 
cholesterol from hepatocytes to peripheral tissues. 
Figure-2  Structure of  LDL 
 
 
Metabolism of LDL and its receptors 
   The LDL is rich in cholesterol. LDL helps to transport cholesterol from 
liver to extrahepatic tissues. It is taken up by the peripheral tissues like 
skeletal muscles and adipocytes etc through receptor mediated process .LDL 
binds to its receptors which are located on the cell surface of the target 
tissues. This receptors recognize apoprotein B 100 22. After binding, the 
receptor and LDL complex is taken up by receptor mediated endocytosis. 
Binding of LDL to its receptor and uptake of cholesterol from LDL is a 
highly regulated process.  
      LDL receptors are located on all cells. But they are abundant in liver 
cells. They are situated in a highly specialized location called  Clathrin 
coated pits. The LDL receptor is a polypeptide. It contains 839 amino 
acids.apo B100 and apoE bind to the extra cellular domain of the receptor. 
The intracellular domain of the receptor is responsible for the clustering of 
LDL receptors into regions of  the plasma membrane termed coated pits. 
When apo B100 binds to the apo B 100 receptor, the receptor –LDL 
complex is internalized by endocytosis. The internalized LDL is then 
degraded by lysosomal hydrolases yielding free fatty acids, phospholipids, 
cholesterol, glycerol and amino acids. 
   The free receptors are recycled and return to the surface of the cell 
membrane to bind further LDL molecules. 70% of LDL is degraded in the 
hepatocytes. The rest 30%  is degraded in the extra hepatic tissues. In 1985 
Michael Brown and Joseph Goldstein were awarded Nobel Prize for their 
work on LDL receptors. 
 
Figure- 3 Uptake and Fate of LDL 
 
 
    The free cholesterol derived intracellularly from LDL is utilized for the 
synthesis of vitamin D3 in skin, bile acids in liver and steroid hormones in 
renal cortex and gonads It is also incorporated into plasma membranes or 
esterified by ACAT and stored within the cell. 
       The level of intracellular cholesterol is regulated through cholesterol 
induced suppression of LDL receptor synthesis and cholesterol induced 
inhibition of cholesterol synthesis. The increased level of intracellular 
cholesterol that results from LDL uptake activates ACAT, thereby allowing 
the storage of excess cholesterol within cells. However, the effect of 
cholesterol induced suppression of LDL receptor synthesis is to reduce the 
rate at which LDL and IDL are removed from the serum. This can lead to 
excess circulating levels of cholesterol. The excess cholesterol tends to be 
deposited within the arterioles, leading to atherosclerosis. 
       PCSK9, a serine protease that destroys LDL receptors in the liver23. 
Estrogen and Thyroxin increase the expression of LDL receptor gene12.  
These hormones have LDL-C–lowering effects through regulation of gene 
expression. 
        Regulation of LDL receptor expression is part of a complex process by 
which cells regulate their free cholesterol content. This regulatory process is 
mediated by transcription factors called sterol regulatory element binding 
proteins (SREBPs) and its cleavage activating protein-Scap.  Scap is a 
sensor of cholesterol content in the endoplasmic reticulum. 
       LDL becomes atherogenic when modified by oxidation24 . This process 
leads to foam-cell formation in arterial lesions. At least two scavenger 
receptors (SRs) are involved (SR-AI/II and CD36). Knocking out either 
receptor in transgenic mice retards the uptake of oxidized LDL by 
macrophages. 
 
Figure - 4 
 
 
LDL Receptor- Related Protein (LRPs)25 
    LRPs, represent a group of structurally related transmembrane proteins. 
This proteins involved in a wide range of biological activities. The activities 
of this group of proteins include nutrient transport, lipid metabolism and 
protection against atherosclerosis.  
LDL receptor related protein family include  
 LRP 1 also known as α β macroglobulin receptor. 
 LRP 1b 
 LRP 2 also known as megalin 
 LRP 4   
 LRP 5/6 
 LRP 8 also called apo E receptor 2 
 VLDL Receptor 
  LRP 1 is expressed in numerous tissues. This receptor involved in  
 Modulation of platelet derived growth factor receptor-ȕ signaling 
 Transport of lipoprotein 
 Regulation of cell surface protease activity 
 The control of cellular entry of viruses and bacteria 
    Regulation of  platelet derived growth factor receptor-ȕ ( PDGFR ȕ ) 
activity mediates the protective effects of LRP 1 in development of 
atherosclerosis.  
       LRP 2 is located on the surfaces of epithelial cells and in endosomes. 
LRP 2 is involved in the reabsorption of variety substances from the renal 
tubules. This protein interacts with lipoproteins, vitamins, vitamin binding 
proteins, hormones, proteases and protease inhibitor complexes. 
LDL and its clinical application 
          Positive correlation exists between plasma LDL concentration and the 
incidence of CVD. A small fraction of cholesterol is taken up by the 
macrophages. This is not a normal regulated pathway. Elevated levels of 
modified LDL, that is oxidized LDL increases the fraction of cholesterol 
taken up by macrophages. LDL crosses the endothelial layer of arterial 
walls, and are taken up by the scavenger cells and macrophages. This is the 
starting point of atherosclerosis. This increases the risk of Myocardial 
infarction. These cells become engorged with cholesterol, and form foam 
cells. They get deposited in the sub endothelial space. This will trigger the 
formation of atheromatous plaque. These procoagulant changes increases 
the risk of thrombosis and coronary artery disease. 
    Insulin and T3  triiodo thyronin enhance the binding of LDL to 
hepatocytes. Corticosteroids have the opposite effects. This is the reason for 
elevated serum LDL level, and increased risk of atherogenic vascular 
disease in patients with uncontrolled diabetes and hypothyroidism. Defect in 
LDL receptor synthesis leads to familial hypercholesterolemia.  
 
  
 
 High Density Lipoproteins 
    HDL transport cholesterol from extra hepatic tissues to the hepatocytes. 
Lipoprotein particles may be distinguished by their electrophoretic 
mobilities. Mature  HDL particles have α mobility; LDL particles show β 
mobility. It has highest density among all lipoproteins. The composition of  
HDL includes lipids - 60% and protein -40%. 
 The lipid components are 
 Cholesterol- 25% 
 Phospholipid-30% 
 Triglyceride- 5% 
The protein component 
 Apo A1, A2 
 Apo C 
 Apo E 
                             
 
Figure – 5  Structure Of HDL 
 
      HDL serves as a plasma reservoir of apo E and apo C. These 
apoproteins are transferred to Chylomicron and VLDL. HDL is synthesized 
in liver cells and also in intestinal mucosal cells. Hepatic HDL- apo A and 
apo C are synthesized by polysomes on the rough endoplasmic reticulum. 
They are assembled with lipids to form the nascent HDL, which is released 
into the circulation. Intestinal HDL – apo A is synthesized by polysomes on 
the rough endoplasmic reticulum. It is assembled with lipids to form nascent 
HDL which is released into the circulation from mucosal cells of intestine26.  
Apo C, apo E are only synthesized in the liver. The nascent HDL is also 
known as discoidal HDL. This nascent HDL contains discoid phospholipid 
bilayer and free cholesterol. 
Metabolism of HDL 
         The free cholesterol derived from peripheral cells are taken up by the 
HDL. The apo A 1 of HDL activates lecithin cholesterol acyl transferase 
[LCAT]. The LCAT binds to the discoidal HDL. From the cells, the 
cholesterol is transported by an efflux pump called cholesterol efflux 
regulator protein which is an ABC transporter. 
          LCAT of plasma binds with nascent HDL discs and gets activated by 
apo A 1 and apo C II of HDL. This will transfer acyl groups from HDL –
Phospholipids to the free cholesterol. Thus lysophospholipids and 
cholesteryl esters are produced. The cholesterol esters are hydrophobic, 
moves to the interior of  the HDL disc. 
         This reaction continues till HDL becomes spherical with lot of 
cholesterol esters are formed. This HDL particle is called as HDL 3 or 
spherical HDL or mature HDL. 
            Mature HDL are taken up by hepatocytes by apo A 1 mediated 
receptor mechanism. HDL is taken up by hepatic scavenger receptor        
B1[ SR- B 1]. Phospholipids and triglycerides of HDL are hydrolyzed by 
hepatic lipase. So that cholesterol esters are released into liver cells. The 
cholesterol within the hepatocytes is utilized for the synthesis of bile acids 
or excreted as such in bile. Androgens increase HL activity, which accounts 
for the lower HDL-C values observed in men than in women. Estrogens 
reduce HL activity, but their impact on HDL-C levels in women is 
substantially less than that of androgens on HDL-C levels in men. 
     When HDL 3 remains in circulation, the cholesterol ester from HDL is 
transferred to VLDL, IDL, and LDL by a cholesterol ester transfer protein 
(CETP). Triacyl glycerol from VLDL, IDL, and LDL is transferred to HDL 
in exchange for cholesterol ester. The HDL particles which are rich in 
triacyl glycerol and spherical are called HDL 2. These particles are acted 
upon by hepatic triglyceride lipase (HTGL) before being taken up by the 
scavenger receptors in liver. The reverse cholesterol transport needs the 
activity of LCAT, CETP, and apo D. 
Clinical significance of HDL 
       There is an inverse relationship between the level of HDL  in plasma 
and the incidence of myocardial infarction. As it is anti atherogenic or 
protective in nature, HDL is known as good cholesterol. HDL also may 
protect against atherogenesis by mechanisms not directly related to reverse 
cholesterol transport. These functions include putative anti-inflammatory, 
anti-oxidative 27activities. Increased fish and reduced carbohydrate 
consumption both are associated with higher HDL-C. 
 
Lipoprotein (a) 
               LP(a) is a special type of lipoprotein . It is not present in all 
person. It is elevated only in some persons. It may be present in 20% of 
normal individuals. In remaining 80% of population, LP(a) is not present in 
the serum in detectable amounts. It is attached to apo B 100 by a disulphide 
bond. It is highly atherogenic. It inhibits fibrinolysis. It is strongly 
associated with myocardial infarction. It is sometimes called as little rascal. 
     In 20% of population , LP(a) concentration in plasma is found to be more 
than 30 mg/dl. These individuals are more susceptible for heart attack at a 
younger age. Indians have a higher concentration of LP(a) than western 
population. 
Clinical importance 
 The person having LP(a) are more susceptible to heart attack at the 
younger age group of 30- 40 years. 
 Serum levels > 30mg/dl increases the risk of myocardial infarction by 
3 times. 
 When the increased LP(a) level is associated with increased LDL, the 
risk of myocardial infarction increases further. 
 
 
Transport of dietary (Exogenous) lipids 28 
     Dietary triglycerides are hydrolyzed by the pancreatic lipase, then 
emulsified with bile acids to form micelle. Chylomicrons formed from the 
dietary triglycerides and cholesterol. It also contains fat soluble vitamins. 
Chylomicron are absorbed from the intestinal epithelial cells into the lymph 
and finally enters the systemic circulation. 
    Lipoprotein lipase is an enzyme which is located on the capillary 
endothelium of heart, adipose tissue and skeletal muscles. Lipoprotein lipase 
requires apo CII as a cofactor for its optimal functioning. Lipoprotein lipase 
hydrolyzes chylomicron into triglycerides and release free fatty acids. Free 
fatty acids are taken up by the adjacent myocytes and adipocytes. The free 
fatty acid is either oxidized to generate energy or esterified and stored. 
Some of the free fatty acid binds with albumin. Free fatty acid albumin 
complex are transported to various organs, especially liver. Chylomicron 
becomes chylomicron remnant, which are cleared from the circulation by 
hepatocytes through apo E receptors. 
 
 
 
 
Figure- 6  Llipoprotein Metabolic Pathway 
 
Transport of hepatic (Endogenous) lipids 
   Transport of apo B containing lipoprotein from the liver to peripheral 
tissues. VLDL is secreted from the liver to plasma. VLDL is hydrolyzed by 
lipoprotein lipase in heart, skeletal muscle, adipocyte. VLDL is converted to 
IDL, 40-60% of IDL is cleared by the hepatocytes via LDL receptor 
mediated endocytosis.LDL is formed from IDL by hepatic lipase.LDL 
contain apo B100 which is the only lipoprotein and cholesteryl ester which 
is the main core lipid in LDL. LDL contains greater than half of plasma 
cholesterol. Three fourth of circulating LDL is removed by hepatocytes. 
LDL receptor gene expression is enhanced by hormone such as thyroxin, 
estrogen. Hence thyroxin and estrogen have LDL lowering effect. 
Reverse cholesterol transport29 
              The scavenging action of HDL play a role in the removal of  
cholesterol  from peripheral extra hepatic tissues to liver. Free cholesterol 
from macrophages are removed by this transport. Thereby reduces the risk 
of atherosclerosis. HDL has antiatherogeneic and antioxidant properties. 
HDL cholesterol is also known as good cholesterol. LDL cholesterol is also 
known as bad cholesterol. 
Figure-7  Reverse Cholesterol Transport
 
      
     Cholesterol is transported from the peripheral cells to liver and intestine. 
In contrast to atherogenic apoB 100, the apo A1 containing HDL appears to 
be antiatherogenic. Other apoproteins on HDL are apo A11, apo C, apo E. 
HDL acquires free cholesterol from peripheral tissues including arterial wall 
foam cells. ABC-1 which is a cholesterol transport protein facilitates the 
important step in reverse cholesterol transport. The acquired free cholesterol 
is then esterified by the circulating enzyme lecithin cholesterol acyl 
transferase (LCAT). The esterified cholesterol then moves into the core of 
HDL. Apo C1 in HDL activates LCAT and thus facilitates free cholesterol 
esterification. Cholesteryl ester transport protein is responsible for transfer 
of cholesteryl ester of HDL to VLDL, IDL, LDL, chylomicron remnant. 
This is thought to be a primary mechanism by which HDL protects from 
atherosclerosis.HDL enhances antioxidant enzyme activity which protects 
LDL from oxidative stress .Low level of HDL is associated with increased 
risk atherosclerosis. The elevation of apo B containing lipoprotein including 
lipoprotein (a) which deliver cholesteryl ester to the vessel wall, and 
increases the risk of atherosclerosis. 
 
 
Table-1 
 
 
Causes of Dyslipidemia30 
Primary causes 
         1.Familial or genetic due to single gene defect 
         2.Multifactorial or polygenic which have multiple genetic, dietary and 
physical activity related causes. 
 
 
 
                                          Table-2 
Table – Fredrickson-Levy-lees classification of hyperlipoproteinemia 
Type  Lipoprotein elevation 
I Chylomicrons 
IIa LDL 
IIb LDL+VLDL 
III IDL 
IV VLDL 
V VLDL+ Chylomicrons 
 
Secondary causes 
 1.  Hypothyroidism 
 2. Chronic kidney disease 
 3. Diabetes mellitus 
 4. Obstructive liver disease 
 5. Obesity 
 6. Cushing’s syndrome 
 7. Alcohol 
 8. Drug induced 
                                             Table-3 
                               SECONDARY CAUSES  
 
 
DISORDER MAJOR LIPID EFFECT 
Diabetes mellitus Triglycerides  
Nephrotic syndrome Triglycerides  
Alcohol use Triglycerides  
Oral OC Pill use Triglycerides  
Estrogen  Triglycerides  
Glucocorticoid excess Triglycerides  
Hypothyroidism Cholesterol  
liver disease Cholesterol  
 
 
Dyslipidaemia in thyroid disease 
    Hypothyroidism is associated with reduction in the function of LDL 
receptors31. Reductions in the hepatic LDL receptors are associated with 
delayed clearance of LDL that results in increased LDL cholesterol. 
Hyperthyroidism is associated with decreased LDL cholesterol level. All 
patients with elevated LDL Cholesterol should be screened for 
hypothyroidism. Treatment of thyroid disease usually corrects the 
hypercholesterolemia. 
Dyslipidaemia associated with chronic kidney disease 
    In chronic kidney disease increased triglyceride rich lipoprotein is due to 
decreased lipoprotein lipase and hepatic lipase activity. There is increased 
apolipoprotein C-III in the setting of renal insufficiency. Lipoprotein lipase 
activity is inhibited by apoC-III. Thus elevated triglyceride is associated 
with increased apoC-III levels. apoC-III appears to increase plasma 
triglyceride by 
      1.Modulates the affinity to bind triglyceride rich lipoproteins to 
receptors on    hepatocytes and proteoglycans. 
      2.Decreases the lipolysis of triglyceride by lipoprotein lipase. 
  
      The effects of chronic kidney disease are mediated via increased 
oxidative stress, chronic inflammation, other toxic components of uremia. 
This results in changes in the structure and function of lipoproteins. In 
chronic kidney disease HDL is contaminated by serum amyloid. Normally 
HDL has antioxidant activity. In chronic kidney disease antioxidant activity 
of HDL is decreased32, and HDL becomes dysfunctional. This dysfunctional 
HDL is less efficient in reverse cholesterol transport from peripheral tissues 
such as macrophages to hepatocytes.  
    
       Lipoprotein abnormalities in chronic kidney disease include increased 
triglyceride, LDL, VLDL, and decreased HDL. Dyslipidaemic triad include 
increased triglycerides and VLDL and decreased HDL. Postprandial 
clearance of triglyceride is also reduced in chronic kidney disease. There is 
impaired catabolism of chylomicron remnants and VLDL remnants. 
Dyslipidaemia in diabetes mellitus 
     Insulin resistance is the cause for abnormalities in lipoprotein 
metabolism which include elevated triglyceride. There is reduced  
hydrolysis of triglyceride in VLDL by lipoprotein lipase, reduced free fatty 
acid trapping, increased influx of free fatty acid to the hepatocytes due to 
decreased inhibition of hormone sensitive lipase by insulin, resulting in 
increased synthesis of VLDL in the liver. Type 1 diabetes mellitus patients 
are usually not dyslipidaemia if  their glycemic control is good . Diabetic 
keto acidosis is commonly associated with hypertriglyceridemia. This is 
because of increased influx of free fatty acids from adipose tissues to liver. 
Here the lipid abnormalities respond well to the administration of insulin. 
Dyslipidaemia is common in patients with type 2 diabetes mellitus though 
their  glycemic control is good. Type 2 diabetes mellitus is frequently 
associated with high level of insulin and insulin resistance. The Insulin 
resistance has multiple effects on lipid metabolism.  
 
Effects of Insulin resistance on lipid metabolism 
1. Reduced catabolism of chylomicrons and VLDL due to reduced 
lipoprotein lipase activity. 
2. Increased synthesis of fatty acids in the hepatocytes 
3. Increased VLDL production in the liver 
4. Increased release of free fatty acid from the adipocytes. 
Patients with diabetes typically have higher triglycerides and lower HDL. 
Triglyceride levels are positively correlated with the level of insulin 
resistance. Three characteristic lipid abnormalities in diabetes are33  
1. Hyper triglyceredemia 
2. Low HDL 
3. Elevated small dense LDL particles  
     Increased serum LDL levels are generally not a feature of type 2 
diabetes. If there is an elevation in serum LDL level, suspect - underlying 
lipoprotein abnormalities or renal involvement. Atherosclerosis is the  
common cause of mortality in patients with diabetes. Hence it is essential to 
treat dyslipidaemia. The various trials of  cholesterol reducing measures 
show that HMGCoA reductase inhibitors are highly efficacious in the 
prevention of cardiovascular disease in diabetes. 
Dyslipidaemia and Obesity 
       Obesity is frequently associated with Hyperlipidaemia. Excessive 
caloric intake causes hypertrophy of adipocytes and increased visceral 
adipose tissue. Adipose tissue is an endocrine organ which secretes many 
pro inflammatory cytokines and adipokines. The proinflammatory cytokines 
are tumor necrosis factor alpha (TNF α), interleukin IL- 1, IL- 4, IL- 6, 
Monocyte Chemo tactic Protein (MCP-1), Interferon Ȗ (INF  - Ȗ) and nitric 
oxide synthase 1 (NOS- 1)34. These proinflammatory cytokines initiate 
inflammation and causes insulin resistance and finally dyslipidaemia. 
       Patients with obesity have increased adipocyte mass and decreased 
insulin sensitivity. Excessive fatty acids are released from the adipose tissue 
and delivered to the liver. The free fatty acids in the hepatocytes are re 
esterified to form triglycerides and they are packaged into VLDL and 
secreted into the systemic circulation. Intake of simple carbohydrates also 
increases the production of VLDL. In obese patients plasma HDL is low. 
Physical activity is associated with increased plasma HDL and reduced 
apoB containing lipoproteins.  
         
 
         Normal adipocytes (smaller and not hypertrophied) secrete increased 
amount of adiponectin. Adiponectin helps to prevent insulin resistance, 
inflammation and Dyslipidaemia. Under the influence of adiponectin  
macrophage secrete anti-inflammatory substances such as interleukin IL- 
10. 
        Since obesity is a risk factor for cardiovascular diseases, and negatively 
affecting levels of total cholesterol, LDL, HDL, and Triglyceride, a strong 
focus of a cardio protective dietary recommendation is- to achieve ideal 
body weight. 
     Waist- to-hip ratio (WHR) and waist circumference measure abdominal 
adiposity. This is an indicator of  cardiovascular risk events..  
Dyslipidaemia and Cushing syndrome  
      Dyslipidaemia seems to be less frequent metabolic complication in 
Cushing's syndrome.  Insulin resistance plays an important role in 
determining lipid abnormalities35. Excess glucocorticoid increases VLDL 
production. There by increases   triglyceride level. These Patients may have 
mild elevation of serum LDL cholesterol.    
 
 
 
Dyslipidaemia and chronic alcoholism 
        Hypertriglyceridemia is the most common lipoprotein abnormality in 
alcoholism. Regular alcohol consumption inhibits oxidation of free fatty 
acids in liver. Increased free fatty acids in liver promote the synthesis of 
hepatic triglyceride and secretion of VLDL. Alcohol intake may be 
classified into ‘light’, ‘moderate’ and ‘heavy’ consumption. This 
classification is based on the quantity of alcohol intake that is in the form of 
daily intake of pure ethanol.  
‘Light–moderate’ consumption- 1 to 2 drinks /day or <30 g of alcohol/day 
 ‘Heavy consumption’- ≥γ drinks /day or >30 g alcohol /day 36.  
       Regular moderate consumption of alcohol is associated with light to 
moderate increase in plasma HDL cholesterol. However regular 
consumption of alcohol is associated with many side effects like 
hypertension, gastritis, malabsorption, pancreatitis, fatty liver, hepatitis, 
cirrhosis, deficit in cognitive function and judgment, dementia, tolerance, 
dependence hence it is not recommended.  
 
 
 
Dyslipidaemia and estrogen 
        Estrogen decrease serum LDL level and raises HDL and triglyceride. 
The ratio of HDL: LDL is raised. Plasma lipid profile should be monitored 
when oral contraceptive pills or hormone replacement therapy with estrogen 
is started. Administration of low dose estrogen containing preparations or 
transdermal patch can reduce the effect of externally administered estrogen 
on lipid profile. 
Drugs causing dyslipidemia34 
      Thiazide diuretics 
      Cyclosporine 
      Niacin toxicity 
      Estrogen 
     Anabolic steroids 
     Bêta blockers  
     Bile acid binding resins 
     Retinoic acid  
     HIV protease inhibitors 
     Growth hormone 
     Isotretinonin 
Complications of Dyslipidaemia 
 Atherosclerosis 
 Stroke  
 Myocardial infarction  
 Coronary artery disease 
 Peripheral vascular disease 
Dyslipidaemia and atherosclerosis12 
     Dyslipidaemia contributes to the pathogenesis of atherosclerosis and 
atherosclerosis-induced conditions. These include coronary artery disease 
(CAD), ischemic stroke, and peripheral vascular disease 
    Cardiovascular and cerebrovascular ischemic diseases are the leading 
causes of morbidity and mortality all over the world. A major cause for the 
development of ischemic disease is associated with the development of 
atherosclerosis as a complication of Dyslipidaemia. 
      Increased LDL cholesterol, decreased HDL cholesterol, Smoking, 
Systemic hypertension, Type II diabetes mellitus, Increase in age and a 
positive history of premature coronary artery disease events  (men<55yrs, 
women<65 yrs) in a first degree relative are important risk factors for 
cardiovascular disease. The important measure to prevent premature 
coronary heart disease is to control the modifiable risk factors like  diet, 
smoking habit etc , which  account for 85% of excess risk for premature 
coronary events. 
 National Cholesterol Education Program (NCEP) Guidelines for 
Assessing Risk 
          In 2001, the existing National Cholesterol Education Program, Adult 
Treatment Panel (ATP) III guidelines were formed and it was updated in 
2004.  
The key features of the update are  
1. Abandoning the concept of a threshold LDL-C level that must be 
exceeded before initiating cholesterol-lowering therapy in CHD or 
CHD equivalent patients;  
2. Adopting a new target LDL-C level (<70 mg/dl) for very high-risk 
patients;  
3. Employing a "standard statin dose" (a dosage sufficient to lower 
LDL-C by 30-40%) as a minimum therapy when initiating 
cholesterol-lowering therapy with Statins. 
 
 
 Table – 437 
 
 
a) Adopted from the US National Cholesterol Education program (NCEP) 
;2004 Revision of adult treatment panel III (ATP III) 
LDL Cholesterol Lowering Treatment Guidelinesa 
Risk category LDL-CH 
goal (mg/dl) 
LDL CH level 
for initiation 
of lifestyle 
changes 
LDL CH level 
for initiation 
of drug 
therapy 
(mg/dl) 
Very high risk 
CAD/CAD equivalentb + 
onec 
< 70e All subjects All subjects 
High risk 
CAD or CAD equivalent 
< 100e All subjects All subjects 
Moderately high risk 
≥2  CAD risk factors + 10 
year CAD riskd  10-20% 
< 130 
(optimal < 
100f) 
≥ 100g 
 
≥ 130 (100-
129f) 
Moderate risk 
≥2   CAD risk factors + 
10 year CAD riskd  < 
10% 
< 130 ≥ 130g 
 
≥ 160 
Low risk  
0-1 CAD risk factor 
 
< 160 ≥ 160g ≥ 190 (0ptional 
160-189f) 
b) CAD equivalent include – diabetes mellitus; 10 yr CAD risk >20%; 
peripheral vascular disease; abdominal aortic aneurysm; symptomatic 
carotid artery disease. 
c) One additional feature from (a) ≥2 CAD risk factors (b) single 
uncontrolled CAD risk factors (c) diabetes mellitus (d) metabolic syndrome 
(e) acute coronary syndrome. 
d) As per risk assessment tables from the Framingham Heart Study 
e) When LDL cholesterol is near or below the goal value, then a statin dose 
to lower LDL CH by 30-40% should be employed. 
f) Patients with severe or multiple risk factors. 
g) Any subject who has life style related risk factors, such as obesity, 
physical inactivity, smoking, etc. is a candidate for life style change of the 
risk factors regardless of LDL CH level. 
 
Risk Assessment 
      Severity of a patient's risk determines the intensity of treatment of 
Dyslipidemia. 66% of men and 50% women are affected. This high 
prevalence rates mandate that all adults of age ≥ β0 years and children with 
high risk, an assessment of their risk of developing CVD. 
 Risk factors for of developing an ischemic stroke include, 
   1. Patients with previous history of CAD, or TIA     
   2. Patients with Type II DM.  
       These patients are at increased risk. They have to be managed 
intensively to improve plasma lipid profile. Others who have not had a prior 
CVD event need monitoring of plasma lipid profile and assessment of risk 
factors for CVD to determine whether the treatment to decrease lipid-related 
risk is necessary. 
       Fasting Lipid levels (total cholesterol, triglycerides, LDL-C, HDL-C, 
and non-HDL-C) and blood sugar should be measured . The LDL-C is not 
measured by direct method. The LDL-C is calculated by using this 
formula:[total cholesterol – (HDL-C) – (triglycerides/5) = LDL-C] 38. Non-
HDL-C is calculated as follows: total cholesterol – HDL-C = non-HDL-C. 
The classification of plasma lipid values is shown in Table. 
 
 
 
 
Table- 5 
Classification of plasma lipid levels (mg/dl)a 
Profile  Values  Inference  
Total cholesterol < 200 
200-239 
≥ β40 
Desirable 
Borderline 
High  
HDL-CH < 40 
> 60 
Low (< 50 for women) 
high 
LDL-CH < 70 
< 100 
100-129 
130-159 
160-189 
≥190 
Optimal for very high risk 
Optimal 
Near optimal  
Borderline high  
High 
Very high 
TGL <150 
150-199 
200-499 
≥500 
Normal 
Borderline high 
High 
Very high 
 
a2001 National Cholesterol Education Program guidelines.  
        Measurement of apoA-I and apoB afford better risk prediction of lipid-
related risk than LDL-C and HDL-C. However, lack of an established 
national reference laboratory for quality control of these apolipoprotein 
assays has precluded formal adoption of apoA-I and apoB measurements by 
the NCEP thus far. Despite this, targets for apoB levels have been 
established by the American Diabetes Association for the management of 
patients with type 2 diabetes mellitus.   
Risk Factors for coronary artery disease39 
1. Men >45 yrs, women >55yrs 
2. Hypertension 
3. Smoking 
4. Low HDL-CH (<40 in men, ,50 in women) 
5. High LDL CH ≥160 or total CH ≥β40 
6. Family history of MI, before 55yrs (Men), 65 yrs (women) 
7. Diabetes 
8. Obesity  
        Diabetes is regarded as CAD-equivalent and hence the lipid management 
of diabetes patients is important in as in persons with established vascular 
disease . 
 Management of Dyslipidemia 
 Nonpharmacological treatment 
 Pharmacological treatment 
 Other approaches like surgeries 
 Nonpharmacological treatment40 
 Dietary modification 
 Weight loss 
 Aerobic exercise 
 Increased physical activity 
 Lifestyle modification 
Table- 6 
Macronutrient Recommendations for the TLC(therapeutic lifestyle 
change)  diet 
Component Recommended intake 
Total fat 25-35% of total calories 
Saturated fat Less than 7% of total calories 
Polyunsaturated fat Up to 10% of total calories 
Monounsaturated fat Up to 20% of total calories 
Carbohydrates 50-60% of total calories 
Cholesterol <200 mg/day 
Dietary  fiber 20-30 gram/day 
Plant sterols 2 gram/day 
Proteins  Approximately 15% of total calories 
Total calories  To achieve and maintain desirable body weight 
 
Pharmacological treatment41 
1. HMG-CoA reductase inhibitors (statin) 
 Atorvastatin 
 Rosuvastatin 
 Simvastatin 
 Pravastatin 
 Lovastatin 
 Pitavastatin 
2. Bile acid sequestrants (resins) 
 Cholestyramine 
 Colestipol 
3. Lipolysis and triglyceride synthesis inhibitors 
 Nicotinic acid 
4. Lipoprotein lipase activators (PPARα activators,Fibrates) 
 Clofibrate 
 Bezafibrate 
 Fenofibrate 
 Gemfibrozil 
5. Sterol absorption inhibitor 
 Ezetimibe 
6. Cholesteryl ester transfer protein (CETP) inhibitors 
 Torcetrapib 
 Anacetrapib 
7.Omega 3 fatty acids 
 Eicosopentae noic acid (EPA) 
 Docosahexaenoic acid (DHA) 
Drug therapy of Dyslipidemia 
HMG-CoA Reductase inhibitors 
       Statins are the most efficacious hypolipidaemic drugs. They act by 
competitively inhibit HMG-CoA reductase enzyme. 3-Hydroxy-3methyl 
glutaryl coenzyme A is converted to mevolanate by HMG-CoA reductase 
enzyme which is the rate limiting step in de novo cholesterol biosynthesis. 
They  reduce cholesterol synthesis, which results in compensatory increase 
in LDL receptor expression on hepatocytes. There is increased uptake and 
degradation of LDL and IDL. 
         
 Statins were obtained from a mold, Penicillium citrinum42. In 1976 Endo 
and colleagues identified that statins are inhibitor of cholesterol 
biosynthesis.  They named the drug as Mevinolin which was isolated from 
Aspergillus terreus. Now it is known as Lovastatin. Chemically modified 
derivatives of Lovastatin include Pravastatin and Simvastatin.  
          Lovastatin , Pravastatin and Simvastatin  are fungal derivatives while 
Atorvastatin ,Fluvastatin ,Rosuvastatin, Cerivastatin and Pitavastatin are 
synthetic compounds. The side group of statin is structurally similar to 
HMG-CoA. Lovastatin , Pravastatin and Simvastatin  contain a 
hexahydronaphthalene ring. Heptanoic acid side chain of Atorvastatin 
,Fluvastatin ,Rosuvastatin and Pitavastatin have similar structure with that 
of  HMG-CoA intermediate. 
        Monacolin K- HMG-CoA reductase enzyme inhibitor. It is chemically 
identical to Lovastatin. It is obtained from the yeast, known as Monascus 
purpureus which grows on red rice.  
 
 
 
 
Pharmacokinetics  
        Lovastatin and simvastatin are lactone prodrugs. They are less soluble 
in water than other statin. They are enzymatically hydrolyzed into active 
hydroxy acid forms43. 
          Atorvastatin, rosuvastatin, pravastatin, fluvastatin and pitavastatin are 
administered in the active, hydroxyl acid form. All statins are given by oral 
route. The absorption is enhanced by food except Pravastatin. All statins 
undergo extensive first-pass metabolism in the hepatocytes. 
          Oral bioavailability varies between 5% and 60% of administered 
doses. They are metabolized in the liver by CYP enzyme and eliminated 
through bile44.  Plasma concentration of statins increase in liver failure. 
Under steady-state conditions, small amounts of the parent drug and its 
metabolites produced in the liver can be found in the systemic circulation. 
About  90-95%  is bound to plasma proteins. Pravastatin is 50% bound to 
proteins 
          Peak plasma concentration will be achieved within 4 hours. The rate 
and extent of absorption of Atorvastatin is affected by time of 
administration45,, while pharmacokinetic properties of Rosuvastatin are 
unaffected46.  However for both drugs, the lipid lowering effects are similar 
whether given in the morning or evening 
Mechanism of action of statins47 
       Statins exert their effect by inhibiting HMG-CoA reductase enzyme. 
The major effect of statin is the reduction of LDL levels. The reduction of  
HMG-CoA to mevalonate is catalyzed by HMG-CoA reductase. It is the 
rate limiting step. 
Figure- 8 
 
 
Regulation of Cholesterol biosynthetic pathway. 
           In 1940 Konrad Bloch described that all carbon atoms of cholesterol 
are derived from acetyl CoA. He got Nobel Prize in 1964. The cholesterol 
biosynthetic pathway was described by Sir John Cornforth and Vladimir 
Prelog. They got Nobel Prize in 1975. Liver, adrenal cortex, testis, ovaries 
and intestine are the major sites of synthesis of cholesterol. 
             Statins lower plasma lipid levels by inhibiting cholesterol 
biosynthesis. Reduced plasma cholesterol levels causes increased expression 
of LDL receptor gene. Intracellular reduction in free cholesterol content 
within the hepatocytes result in cleavage of membrane bound SREBPs by 
protease. It is translocated to the nucleus, which enhances transcription of 
LDL gene and increases the number of LDL receptors. Decreases the 
number of LDL receptor destruction. The number of LDL receptors on 
parenchymal cells of liver are increased that result in enhanced clearance of 
LDL from the plasma, thereby reducing LDL cholesterol.  
         Various studies support that statin induces LDL receptors that interact 
with both apoB-100, apoE. This results in increased clearance of LDL 
precursors VLDL, IDL. Statins also reduce synthesis of VLDL from the 
liver. This is secondary to reduced cholesterol synthesis.  The cholesterol is 
an important content of VLDL.  Statin also reduces triglycerides and LDL in 
patient with homozygous familial hypercholesterolemia. 
                      
 
Figure- 9 Mechanism Of Action Of Statins 
 
 
Triglyceride Reduction by Statins 
     Triglyceride levels >250 mg/dl are reduced substantially by statins, and 
the percent reduction achieved is similar to the percent reduction in LDL-C. 
Accordingly, the patients with hypertriglyceridemia who are treated with the 
maximum doses of the most potent statins showed, reduction in LDL-C and 
triglycerides upto 35-45%. The efficacy of triglyceride lowering by 
Pitavastatin in patients with baseline triglyceride levels >250 mg/dl is 
currently unknown. 
Effect of Statins on HDL-C Levels 
       Most studies of patients treated with statins have systematically 
excluded patients with low HDL-C levels. In studies of patients with 
elevated LDL-C levels and gender-appropriate HDL-C levels (40-50 mg/dL 
for men; 50-60 mg/dl for women), an increase in HDL-C of 5-10% was 
observed, irrespective of the dose or statin employed. However, in patients 
with reduced HDL-C levels (<35 mg/dL), statins may differ in their effects 
on HDL-C levels. Simvastatin, at its highest dose of 80 mg, increases HDL-
C and apoA-I levels more than a comparable dose of atorvastatin (Crouse et 
al., 2000). In preliminary studies of patients with hypertriglyceridemia and 
low HDL-C, rosuvastatin appears to raise HDL-C levels by as much as 15-
20% . More studies are needed to ascertain whether the effects of statins on 
HDL-C in patients with low HDL-C levels are clinically significant. 
Effects of Statins on LDL-C Levels 
        Statins lower LDL-C by 20-55%, depending on the dose and statin 
used. In large trials comparing the effects of the various statins, equivalent 
doses appear to be 
 5 mg of simvastatin =  15 mg of lovastatin 
15 mg of lovastatin  = 15 mg of pravastatin   
 15 mg of pravastatin  = 40 mg of fluvastatin  
20mg of simvastatin = 10 mg of atorvastatin 
 20 mg of atorvastatin = 10 mg of rosuvastatin . 
                LDL-C reducing effect of statins showed,  log-linear relationship 
on dose- response curve. LDL-C is lowered by nearly 6% (from initial 
value) with each doubling of the dose. Maximal therapeutic benefits  on 
plasma cholesterol levels are seen within 7-10 days. 
        Statins improve lipid profile by reducing LDL –C and increasing HDL-
C. These effects of statins on lipid profile have favorable effect in reducing 
CVD events. In addition to lipid lowering effect it also exert other effects , 
that protects individual from ischemic vascular events. This is referred to as 
pleiotropic effect that is not related to their effect on plasma lipid levels.            
 
 
 
 
Figure- 10  Pleiotropic Effects Of Statin 
 
Other actions of statins48 
Improved endothelial function 
Reduced vascular inflammation 
Reduced platelet aggregability 
Increased neovascularisation of ischemic tissue 
Increased circulating endothelial progenitor cells 
Stabilization of atherosclerotic plaque 
Antithrombotic actions 
Enhanced fibrinolysis 
Inhibition of germ cell migration during development 
Statins and Endothelial Function 
          Dyslipidemia can cause endothelial dysfunction by increasing the 
level of free radicals and reducing nitric oxide synthases activity. 
Hypercholesterolemia depresses acetylcholine induced vasodilatation in 
coronary arteries. Treatment with statins stabilize nitric oxide synthase  
mRNA , leading to improved endothelial function. This action is not related 
to plasma lipid lowering effect. 
Statins and Plaque Stability 
               Atheromatous plaque stability is very important than the extent of 
narrowing due to plaque. Atheromatous plaque may rupture and cause 
serious vascular events. Statins reduces the formation of atheromatous 
plaque and decreases the chance to rupture by following mechanism 
1. They inhibit infiltration of macrophages into the intima of vessel wall. 
2. They inhibit release of matrix metalloproteinase from inflammatory 
cells49.  
 This enzyme destroys the extracellular matrix.  This results in 
destabilization fibrous cap of atheromatous plaques. 
      Statins reduce the recruitment of inflammatory cells. They also reduce 
smooth muscle hyperplasia by increasing their cell death and reduces its 
multiplication. Reduced proliferation of smooth muscle cells and enhanced 
apoptosis can regress initial hyperplasia and restenosis. Their role on 
inhibition of proliferation of cells and enhanced rate of apoptosis has 
beneficial effects on malignant tumors. 
Statins and Inflammation 
       Inflammatory cells and processes involved in the pathogenesis of 
atherogenesis. Statins showed an anti-inflammatory activity in animal 
models. Statins reduce baseline plasma C-reactive protein content. CRP is 
an inflammatory marker and also considered as marker for CHD . The 
reduction in CRP level is independent of cholesterol lowering effect of 
statin. Patients with morbid obesity and insulin resistance have high level of 
CRP.  Secondary preventive measures have to be adopted in patients with 
serum CRP level   >3 mg/ lit 
Statins and Lipoprotein Oxidation 
      Oxidized LDL plays an important role in the process of atherogenesis. 
This modified LDL is taken up by the macrophages. This increases the 
recruitment of other inflammatory cells into the vessel wall.  Statins 
decrease the oxidative modification of lipoproteins. 
Statins and Coagulation 
Statins reduce platelet aggregation and reduce the deposition of platelet 
thrombi. In addition, statins decrease the plasma fibrinogen levels. Elevated 
plasma fibrinogen levels are associated with an increase in the incidence of 
CHD. 
Adverse Effects and Drug Interactions 
The satins are devoid of adverse effects and very rarely cause side effects. 
1. Gastro intestinal disturbances50  
2. Mild head ache 
3. Skin rashes 
4. Muscular cramps 
5. Sleep disturbances  
6. Hypersensitivity reaction 
7. Hepatotoxicity  
8. Myopathy  
Hepatotoxicity 
          Elevation of serum aminotransferases can occur in < 1% of patients 
under treatment 51. But liver damage is rare. So liver function tests should be 
done before starting therapy and monitored during therapy. 
            Observational studies and a prospective trial suggest that 
transaminase elevations in patients with nonalcoholic fatty liver disease and 
hepatitis C are not at risk of statin-induced liver toxicity .This is important, 
as many insulin-resistant patients are affected by nonalcoholic fatty liver 
disease and have elevated transaminases. Patients with type 2 diabetes 
mellitus, benefit from lipid-lowering therapy with statins. It is reassuring 
that these patients with elevated transaminases can safely take statins. 
Myopathy 
        The major adverse effect associated with statin use is myopathy. The 
incidence is less than 1 per 1000. It can progress to rabdomyolysis. So 
monitor CPK while on therapy.  
The risk factors for of myopathy and rhabdomyolysis  
1. Increased statin dose and plasma concentrations. including  
2. Elderly patients   
3. Renal failure 
4. Hepatic failure 
5. perioperative periods 
6.  diabetes mellitus 
7. Low BMI 
8. Hypothyroidism  
9. Concurrent use of cyclosporine, gemfibrozil, macrolide, warfarin, , 
antibiotics, digoxin and azole antifungals.  
Drug interactions 
         Refers to alteration of response of one drug by another when they are 
administered simultaneously. It can be divided into pharmacokinetic or 
pharmacodynamic interaction. 
          Gemfibrozil, the drug most commonly associated with statin-induced 
myopathy, due to its inhibitory effect on  hepatic OATP1B1 . Gemfibrozil 
nearly doubles the plasma concentration of the statin hydroxy acids. Other 
fibrates, especially fenofibrate, do not interfere with the glucuronidation of 
statins and pose less risk of myopathy when used in combination with statin 
therapy.  
       Concomitant therapy with simvastatin, 80 mg daily, and fenofibrate, 
160 mg daily, results in no clinically significant pharmacokinetic 
interaction. Similar results were obtained in a study of low-dose 
rosuvastatin, 10 mg daily, plus fenofibrate, 67 mg three times a day. 
Myopathy is more common when nicotinic acid is given concurrently. 
       Drugs that interfere with statin oxidation are those metabolized 
primarily by CYP3A4 and include erythromycin, itraconazole, cyclosporine; 
nefazodone, (phenylpiperazine antidepressant); HIV protease inhibitors; and 
amiodarone. These pharmacokinetic interactions are associated with 
increased plasma concentrations of statins and their active metabolites.  
         Atorvastatin, lovastatin, and simvastatin are primarily metabolized by 
CYPs 3A4 and 3A5. Fluvastatin is mostly (50-80%) metabolized by 
CYP2C9 to inactive metabolites, but CYP3A4 and CYP2C8 also contribute 
to its metabolism. Pravastatin, however, is not metabolized to any 
appreciable extent by the CYP system and is excreted unchanged in the 
urine. Pravastatin, fluvastatin, and rosuvastatin are not extensively 
metabolized by CYP3A4.  
         Pravastatin and fluvastatin may be less likely to cause myopathy when 
used with one of the predisposing drugs. However, because cases of 
myopathy have been reported with both drugs, the benefits of combined 
therapy with any statin should be carefully weighed against the risk of 
myopathy. Although rosuvastatin is not transformed to any appreciable 
extent by oxidation, cases of myopathy have been reported, particularly in 
association with concomitant use of gemfibrozil. Experience with 
pitavastatin is limited. There are no data regarding myopathy and 
rhabdomyolysis that might be associated with its use. 
      Despite the rarity of 10-fold elevations of CK, many patients complain 
of muscle aches (myalgias) while taking statins. It is unclear if such 
myalgias are caused by taking a statin. In one clinical trial involving 20,000 
subjects randomized to simvastatin (40 mg daily) or placebo, it was 
observed over the 5 years of the study that one-third of patients complained 
of myalgia at least once, whether the active drug or the placebo was being 
taken (Heart Protection Study Collaborative Group, 2002). 
       There are few reports of statin induced thrombocytopenia52,53. The 
miscellaneous pathophysiologic mechanisms of statin induced 
thrombocytoprnia can be divided into two major categories. 
1. Decreased platelet production via bone marrow suppression. 
2. Peripheral platelet clearance by immune mechanisms. 
          Replacing vitamin D in patients with a vitamin D deficiency 
reportedly reduces statin-associated myalgias and improves statin tolerance 
(Ahmed et al., 2009). The observation needs to be confirmed, but it is 
potentially significant because vitamin D deficiency is associated with 
myopathy, insulin resistance, and increased incidence of CVD. 
Pregnancy 
Statins cross placental barrier and reaches the fetus. It will affect cholesterol 
synthesis in the fetal tissues. Cholesterol is essential for fetal development. 
Hence Statins are contraindicated during pregnancy and lactation54.   
 
 Therapeutic Uses 
1. Patients with Familial Hypercholesterolemia55 
2. Patients with myocardial infarction 
3. Patients with ischemic stroke 
4. Patients with DM 
        Hepatic cholesterol synthesis is maximal between midnight and 
2:00 A.M. Thus, statins with t1/2 4 hours (all but atorvastatin and 
rosuvastatin) should be taken in the evening. 
       The initial recommended dose of lovastatin is 20 mg and is slightly 
more effective if taken with the evening meal than if it is taken at bedtime, 
although bedtime dosing is preferable to missing doses. The dose of 
lovastatin may be increased every 3-6 weeks up to a maximum of 80 
mg/day. The 80-mg dose is slightly (2-3%) more effective if given as 40 mg 
twice daily. 
        The approved starting dose of simvastatin  for most patients is 20 mg at 
bedtime unless the required LDL-C reduction exceeds 45% or the patient is 
a high-risk secondary prevention patient, in which case a 40-mg starting 
dose is indicated. The maximal dose is 80 mg, and the drug should be taken 
at bedtime. In patients taking cyclosporine, fibrates, or niacin, the daily dose 
should not exceed 20 mg.  Pravastatin therapy is initiated with a 20- or 40-
mg dose that may be increased to 80 mg. This drug should be taken at 
bedtime. Because pravastatin is a hydroxy acid, bile-acid sequestrants will 
bind it and reduce its absorption. Practically, this is rarely a problem 
because the resins should be taken before meals and pravastatin should be 
taken at bedtime. should be weighed against the disadvantages inherent in 
fixed-dose combinations.  
       The starting dose of fluvastatin  is 20 or 40 mg, and the maximum is 80 
mg/day. Like pravastatin, it is administered as a hydroxy acid and should be 
taken at bedtime. 
       Atorvastatin has a long t1/2, which allows administration of this statin at 
any time of the day. The starting dose is 10 mg, and the maximum is 80 
mg/day.  Rosuvastatin is available in doses ranging between 5 and 40 mg. It 
has a t1/2 of 20-30 hours and may be taken at any time of day. Because 
experience with Rosuvastatin is limited, treatment should be initiated with 
5-10 mg daily, increasing stepwise, if needed, until the incidence of 
myopathy is better defined. If the combination of gemfibrozil with 
rosuvastatin is used, the dose of rosuvastatin should not exceed 10 mg. 
             Pitavastatin ≥ is available in doses of 1, β, and 4 mg. There is very 
limited post-marketing experience with this drug. Gemfibrozil reduces 
clearance of pitavastatin and raises blood concentrations. 
             The selection of statins will be based on effects and the economic 
status of the patients. Three drugs (lovastatin, simvastatin, and pravastatin) 
have been used safely in clinical trials involving thousands of subjects for 5 
or more years. The documented safety records of these statins should be 
considered, especially when initiating therapy in younger patients. Once 
drug treatment is initiated, it is almost always lifelong.  
         Baseline determinations of ALT and repeat testing at 3-6 months are 
recommended. If ALT is normal after the initial 3-6 months, then it need not 
be repeated more than once every 6-12 months. Measurements of CK are 
not routinely necessary unless the patient also is taking a drug that enhances 
the risk of myopathy. Because myopathy may develop months to years after 
the start of combined therapy, it is unlikely that routine monitoring for the 
accompanying rise in CK will consistently herald the onset, even if 
monitoring is performed every 3-4 months. 
Statin Use by Children 
          Some statins have been approved for use in children with 
heterozygous familial hypercholesterolemia. Atorvastatin, lovastatin, and 
simvastatin are indicated for children ≥ 11 years. Pravastatin is approved for 
children ≥ 8 years. 
 
Statins in Combination with Other Lipid-Lowering Drugs 
1. Statins can be combined with cholestyramine, colestipol and 
colesevelam for (type II a) familial hypercholesterolemia. 
2. Nicotinic acid can be combined with statins for familial combined 
hyperlipidaemia (type II b). This .combination increase the risk of 
myopathy 
3. Statins can be combined with ezetimibe for treating primary 
hypercholesterolemia 
4. Statins can be combined with fibrates for treating 
hypertriglyceridemia 
         The combination of a fibrate (clofibrate, gemfibrozil, or fenofibrate) 
with a statin is particularly useful in patients with hypertriglyceridemia and 
high LDL-C levels. This combination increases the risk of myopathy but 
usually is safe with a fibrate at its usual maximal dose and a statin at no 
more than 25% of its maximal dose. Fenofibrate, which is least likely to 
interfere with statin metabolism, appears to be the safest fibrate to use with 
statins. Triple therapy with resins, niacin, and statins can reduce LDL-C by 
up to 70%. Vytorin, a fixed combination of simvastatin (10, 20, 40, or 80 
mg) and ezetimibe (10 mg), decreased LDL-C levels by up to 60% at 24 
weeks. 
 
Vitamin D 
History of Vitamin  
             As early as second century AD there are reports of symptoms of 
rickets from historians. In 1650 Francis Glisson wrote a classical account of 
infantile rickets. In 1919 McCollum produced experimental model of rickets 
induced by dietary deficiency. In 1931 Angus and coworkers isolated 
Vitamin D and named it as calciferol. It was later identified as Vitamin D3. 
The structural elucidation was done independently by Otto Diels and Kurt 
Alder. In 1950 both were awarded Nobel prize56. 
       Vitamin D can be synthesized in the skin. It is the major source of 
Vitamin D hence it is not strictly a vitamin. Dietary source is required only 
when sunlight exposure is inadequate. Vitamin D plays an important role in 
the regulation of calcium absorption and homeostasis. It also has a role in 
controlling cell differentiation and proliferation. The actions of vitamin D 
are mediated by interacting with the nuclear receptors that regulate gene 
expression. There is evidence that intake considerably higher than are 
required to maintain calcium  homeostasis reduce the risk of insulin 
resistance, obesity, cardiovascular diseases  and the metabolic syndrome, as 
well as various cancers. Sunlight exposure is inadequate in northern 
latitudes. That results in vitamin D deficiency leading to  rickets in children 
and osteomalacia in adults. 
Table-7 
Vitamin D and its major metabolites and analogs 
Chemical and generic names Abbreviation 
Vitamin D3; Cholecalciferol D3 
Vitamin D2;ergocaciferol D2 
25-Hydroxyvitamin D3;calcifediol 25(OH)D3 
1,25-Dihydroxyvitamin D3;calcitriol 1,25(OH)2D3 
24,25-Dihydroxyvitamin D3;secalciferol 24,25(OH)2D3 
Dihydrotachysterol DHT 
Calcipotriene(calcipotriol) None  
1α-Hydroxyvitamin D2;doxercalciferol 1α(OH)Dβ 
19-nor-1,25-Dihydroxyvitamin D2;paricalcitol 19-nor-1,25(OH)D2 
  
Formation of Vitamin D 
         Vitamin D is a secosteroid. It is produced in the skin from 7-
dehydrocholesterol or ergosterol by the action of ultraviolet radiation 
ranging from 290-315nm57.  7-dehydrocholesterol is an intermediate product 
of minor pathway of cholesterol biosynthesis. It is available in the 
Malpighian layer of epidermis. In the skin , ultraviolet rays break the bond 
between position 9 and 10 of the steroid ring. The steroid ring is opened to 
form secosterol which is a provitamin.The cis double bond between 5th and 
6th carbon atoms, is then isomerised to a trans double bond to give rise to 
vitamin D3 or cholecalciferol, hence vitamin D is called sun-shine vitamin.  
       Vitamin D production in the skin is directly proportional to the 
exposure to sunlight and inversely proportional to the skin pigmentation. 
Skin is the largest organ in the body. It makes about 16% of body weight. It 
receives quarter of the body blood supply. An increase in solar zenith angle 
during November to March shifts the wavelength of Ultraviolet rays to 
longer wavelengths which will not produce the vitamin, hence vitamin 
deficiency is seen in winter. 
Vitamin D is a fat soluble vitamin. Its action is similar to steroid hormones. 
Calcitriol synthesis is subjected to feed back regulation. 
Source of vitamin D and normal serum level 
      The major source (80% to 90%) of vitamin D in humans is derived from 
synthesis of vitamin D3 in the skin from sunlight exposure. The dietary 
supply of vitamin D is minor compared to cutaneous formation. Total-body 
sun exposure to 1 minimal erythemal dose provides the equivalent of 250 to 
500 mcg (10,000 to 20,000 IU) of vitamin D per day. The dietary supply 
contributes to minor sources. 
Dietary sources 
  Fatty fish, fish liver oil, egg yolk,Butter, milk58. 
     25(OH) D is the major circulating form of vitamin D which is used to 
diagnose vitamin D insufficiency, deficiency, or toxicity. Estimation of 
vitamin D is used to monitor the patients receiving vitamin D 
therapy.  Immunoassays include RIAs, electrochemiluminometric assays, 
and immunochemiluminometric assays are available to estimate serum 
25(OH) D level. Liquid chromatography tandem mass spectroscopy 
measures circulating β5(OH) vitamin D and is considered the “gold 
standard.”  
         The serum concentration at which beneficial effects are observed is ≥ 
30ng/ml, serum level between 21 to 29ng/ml is considered insufficient, 
serum level < 20 ng/ml is considered as vitamin D deficiency state. High 
serum 25(OH)D concentration were associated with a favorable serum lipid 
profile. Inconsistent with this, high serum 25 (OH) D were associated with a 
significant decrease of serum triglyceride and LDL level . In the absence of 
adequate sun exposure, at least 800–1000 IU vitamin D3/d may be needed to 
achieve this in children and adults.  
 Activation of vitamin D 
         Vitamin D is a prohormone. The cholecalciferol is transported to liver, 
where hydroxylation at 25th position occurs, to form 25 hydroxy 
cholecalciferol. The hepatic 25 –hydroxylase is a microsomal 
monooxygenase and product of gene CYP27A1. It requires cytochrome 
P450 and NADPH. 25-hydroxy cholecalciferol is the major storage form. In 
plasma, 25-hydroxy cholecalciferol is bound to vitamin D binding protein , 
an alpha -2 globulin.  
          In the kidney, it is further hydroxylated at the 1st position. The 1α 
hydroxylase is located in mitochondria of proximal convoluted tubules and 
a product of the gene CYP27B1. It requires cytochrome P450, NADPH and 
ferrodoxin. Thus 1, 25 –dihydroxy cholecalciferol is generated .Since it 
contains three hydroxyl groups at 1,3 and 25 positions, it is also called 
calcitriol. The calcitriol is the active form of vitamin. It is a hormone. 24, 25 
–dihydroxy cholecalciferol may be formed by hydroxylation of 25 hydroxy 
cholecalciferol at the 24th position, a relatively inactive product. 
         Vitamin D receptors are located on nucleus and plasma membrane. 
The calcitriol binds to vitamin D receptors on nucleus and form 
heterodimeric complex with retinoid X receptor (RXR). This heterodimeric 
complex bind to vitamin D response element on DNA. This results in 
modulation of transcriptional activity of gene which is responsible for the 
vitamin D response. Vitamin D receptors are located on the nucleus of 
various cell types. Vitamin D receptors regulate the expression of more than 
500 genes. This action occurs in minutes. In brain and immune cells vitamin 
D is essential for signal transduction. 
Actions of vitamin D 
Vitamin D regulates calcium homeostasis 
Action on bone  
     Vitamin D activates osteoblast, thereby increases bone mineralization, 
regulates remodeling 
Vitamin D and innate immunity 
      Vitamin D acts as an immune modulator. Syntheses of vitamin D 
receptor, 1 alpha hydroxylase are stimulated by binding of tuberculous 
pathogen to macrophage receptors. This results in up regulation of specific 
gene which is responsible for the production of antimicrobial protein in the 
cell. Vitamin D also effective in childhood asthma and steroid resistant 
asthma. 
 
Vitamin D and metabolic syndrome 
 There is increased risk of hypertension, obesity, glucose intolerance, insulin 
resistance, impaired synthesis and secretion of insulin, type 2 diabetes 
mellitus, metabolic syndrome, myocardial infarction, stroke, peripheral 
vascular disease and asthma. Vitamin D concentration positively correlates 
with HDL cholesterol and negatively with serum triglyceride levels and 
LDL cholesterol. Supplementation with Vitamin D is found to be beneficial 
in all these clinical conditions. 
Vitamin D and Blood pressure 
Various clinical studies have shown that vitamin D deficiency is associated 
with hypertension. Supplementation with vitamin D has beneficial effect on 
blood pressure. Vitamin D reduces rennin synthesis. 
Vitamin D and cancer 
Vitamin D decreases cell proliferation and increases cell differentiation, 
stops the growth of new blood vessels, and has significant anti-
inflammatory effects. Many studies have suggested a link between low 
vitamin D levels and an increased risk of cancer, with the strongest evidence 
for colorectal cancer. There is some evidence that vitamin D intake reduces 
breast cancer risk. 
 
Vitamin D and depression 
Vitamin D intake is associated with significant improvement in depressive 
symptoms. 
Vitamin D and cognition 
Deficiency of vitamin D 
      In children , vitamin D deficiency results in failure to mineralize newly 
formed bone and cartilage matrix, causing defect in growth known as 
Rickets. In adults, vitamin D deficiency causes generalized accumulation of 
under mineralized bone matrix known as Osteomalacia. 
Hypervitaminosis D 
      The dose of vitamin D necessary to cause Hypervitaminosis varies 
widely among patients. Daily ingestion of ≥ 50,000 units per day by a 
person with normal sensitivity to vitamin D and normal parathyroid function 
is associated with poisoning. Signs and symptoms of toxicity are related 
with hypercalcemia. 
Clinical manifestations of vitamin D toxicity include: hypercalcemia, 
hypercalciuria, kidney stones, hyperphosphatemia, polyuria, polydipsia, 
ectopic calcification of soft tissues (kidney and lung), nausea, vomiting, 
anorexia, constipation, headache, and hypertension59 . 
  
 Figure- 11  Metabolism And Biologic Actions Of Vitamin D 
 
Metabolism and biologic actions of vitamin D. The major biologic form of 
vitamin D, vitamin D3, is synthesized in the skin from the precursor(pre-D) 
under direct sunlight. Vitamin D from cutaneous synthesis and nutritional 
sources enters the circulation and is bound to vitamin D–binding protein 
(DBP). A series of enzymatic hydroxylation in the liver and kidneys 
transform vitamin D to biologically active 1,25(OH)2 vitamin D. 
Parathyroid hormone regulates the hydroxylation in kidney. Activated 
vitamin D exerts multiple cardiovascular and non cardiovascular actions. BP 
- blood pressure; GI -gastrointestinal; TG -triglyceride; VLDL -very low 
density lipoprotein 
Requirement of vitamin D 
 Children- 10 mcg (400IU)/ day60 
 Adults -5 to 10 mcg (200IU)/ day 
 Pregnancy and lactation- 10 mcg (400IU)/ day 
 Age above 60years – 600 IU/ day. 
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 MATERIALS AND METHODS 
STUDY CENTRE 
     The present study was carried out in the outpatient department of 
General Medicine and Department of  Nephrology, Government Rajaji 
Hospital, Madurai after obtaining clearance from Institutional Ethical 
Committee , Government Rajaji Hospital, Madurai. 
STUDY POPULATION 
    Patients attending the Outpatient department of Medicine and Nephrology 
, Government Rajaji Hospital, Madurai 
SAMPLE SIZE 
  Total sample was 120 (60+60) cases, those who satisfied the inclusion and 
exclusion criteria. 
COLLABORATING DEPARTMENTS 
This study was carried out in collaboration with 
 Institute of pharmacology, Madurai medical college, Madurai 
 Department of Medicine, Govt. Rajaji Hospital, Madurai. 
 Department of Nephrology, Govt. Rajaji Hospital, Madurai. 
 Department of Biochemistry, Madurai medical college, Madurai.  
 
STUDY DESIGN 
   It was a single centre, open labeled, prospective, interventional study in 
patients with Dyslipidemia. 
 
STUDY PERIOD 
    This study was conducted from February 2013 to August 2014 for a 
period of 19 months. 
1. Literature collection: 6 months 
2. Designing the study: 1 month 
3. Case selection and follow-up : 9 months 
4. Analysis: 1 month. 
5. Interpretation: 1 month. 
6. Discussion: 1 month.  
STUDY DURATION 
    6 months for every patient 
STUDY MATERIALS 
    Drugs 1.Atorvastatin 10 mg 
            2. Atorvastatin 10 mg  and Vitamin D3 1000 IU
 
 
 
DETAILS OF DRUG 
Atorvastatin and vitamin D3 
Brand name - Atorsave D10 
Batch no – ASDH12013 
Manufacturing date - AUG.2012 
Expiry date – JUL.2014 
Drug formulation and strength -Atorvastatin calcium 
                                                   equivalent to Anhydrous Atorvastatin 10 mg 
                                                  Cholecalciferol 1000 IU 
Route of administration – oral 
Dosage – 1 tablet / day at bedtime. 
 
 
 ETHICAL APPROVAL 
     Ethical clearance was obtained from Institutional ethical Committee, 
Government Rajaji Hospital,  Madurai.  Ref.Letter  No .990/E4/3/2012. 
INCLUSION CRITERIA 
1. Age – from 30 yrs to 60 yrs 
Patients can be made to understand easily 
Better cooperation from the patients 
Economical independence 
2. Sex-both male and female  
To monitor the response to treatment in both gender 
       3.   Patients with hypertension with hypercholesterolemia 
       4.   Patient with chronic kidney disease with hypercholesterolemia 
       5.   Subjects willing for the study 
Subjects were explained about the proposed study and need for follow up. 
Only those who were willing were included for the study. 
 
EXCLUSION CRITERIA 
1. Patients with liver disease 
Those with chronic liver disease are excluded as atorvastatin can cause 
hepatic damage. 
2. Patients with hypothyroidism- treatment of hypo/hyperthyroidism will 
correct lipid abnormalities 
3. Patients with history of allergy / hypersensitivity to the drugs 
4. Patients with H/o Excessive alcohol intake 
Alcohol intake can alter the lipid profile 
5. Patient who are already on Atorvastatin 
6. Pregnancy  
7. Lactation  
8. Children 
9. Previous participation 
Those who have participated in similar drug trials elsewhere were excluded 
 
 
 DISCONTINUATION 
1. Patients were given the freedom to quit the study at any time. 
2. Subjects were withdrawn from the study, if they develop any adverse 
effects to drugs. 
METHODOLOGY 
        120 patients with Dyslipidemia were taken into the study. The patients 
were diagnosed to have Dyslipidemia as per laboratory data. Out of 120 
patients, 60 patients were treated with atorvastatin 10 mg/day orally and the 
remaining 60 patients were treated with atorvastatin 10mg and vitamin D3 
1000IU/day orally. In atorvastatin group 30 were Hypertensive and 30 had 
chronic kidney disease (CKD). In atorvastatin vitamin D3 group 30 were 
Hypertensive and 30 had CKD. 
       Patients satisfying the eligibility criteria were included in this study. 
Patients were informed both verbally and in writing by the investigator 
about the nature, significance, implications and the risks of study prior to 
enrollment. These were explained by the investigator in a language and 
terms that were easy to understand by the patient. Informed consent was 
obtained from all the patients personally, dated and signed both by the 
patient and the investigator. The details of the investigator (name, phone 
number and contact address) were given to each and every patient, to enable 
them to contact for any ailments at any time during the study period. 
     The socio- demographic data, age, sex, address, educational 
qualifications, smoking and alcohol intake  were collected at initial visit. 
Clinical examination and lab investigations were done. 
     Patients attended the medicine and nephrology OPD fortnightly to 
procure drugs. During these visits, compliance was checked by counting 
empty drug packs and patients with poor compliance were given counseling 
to adhere to therapy. Adverse drug reactions to drugs were assessed. 
    The treatment efficacy was monitored by doing lipid profile at first, third 
and sixth month of therapy.  Other biochemical parameters like  liver 
function tests ,thyroid function test , complete hemogram, blood sugar, renal 
function test and urine test were also monitored during their visits. The 
results were tabulated and analyzed statistically. 
Statistical analysis 
     Data were entered in Microsoft excel sheet and analyzed by paired t test 
and  independent t  test. 
 
                 
  
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
                              
RESULTS 
     120 patients were recruited for the study. All the patients were followed 
up till the end of the study. There were no dropouts.   Among the 120 
patients analyzed, 57% were male and rest were female (43%). The age 
ranged from 30 to 60 years in both the groups. 
Figure- 12 
                    Gender distribution of patients with Dyslipidemia 
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 Among the 120 patients included in the study, the age related distribution 
were as follows, 11 patients were in the age group 30-39 years, 53 belonged 
to the age group 40-49 years, and 56 belonging to age group 50-59 years. 
The distribution in relation to age and gender is as follows. 
Table- 8 
        Age and Gender distribution of patients with Dyslipidemia 
 
Age (years) Male Female No of patients  
30- 39 7 4 11 
40- 49 31 22 53 
50- 59 31 25 56 
TOTAL 69 51 120 
 
 
 
 
     
 
 
 
                                         
 
Figure- 13 
         Age and Gender distribution of patients with dyslipidemia 
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 Efficacy parameters 
Lipid profile – total cholesterol, LDL, HDL, TG, VLDL were evaluated at 
the base line, third month and 6th month.  
 
Table- 9 
Effect of Atorvastatin on lipid profile in various patient population 
(N=60) 
Lipid profile   Before Atorvastatin 
(n=60) 
  After Atorvastatin 
(n=60) 
      Mean       SD     Mean      SD 
Total cholesterol 238.63 18.627 199.62 18.302 
LDL 159.41 17.840 123.78 14.330 
HDL 40.93 2.253 44.28 2.805 
TG 193.98 49.498 165.23 44.577 
VLDL 38.80 9.900 32.71 9.022 
P<0.05 
 
 
                                        Figure- 14 
Effect of Atorvastatin on lipid profile in various patient population 
(N=60) 
 
 
 
 
 
238.63 
159.41 
40.93 
193.98 
38.8 
199.62 
123.78 
44.28 
165.23 
32.71 
0
50
100
150
200
250
300
Mean TC Mean LDL Mean HDL Mean TG Mean VLDL
Atorvastatin 
baseline
after 6 month
 Table- 10 
 
Effect of Atorvastatin and vitamin D3 on lipid profile in various patient 
population (N=60) 
Lipid profile Before Atorvastatin and 
vitamin D3 (n=60) 
After Atorvastatin and 
vitamin D3 (n=60) 
      Mean       SD     Mean      SD 
Total cholesterol 243.85 18.062 169.32 10.772 
LDL 166.71 17.358 98.20 9.176 
HDL 40.33 2.070 45.32 2.943 
TG 186.57 49.244 129.57 35.999 
VLDL 37.31 9.849 25.80 7.189 
P<0.05 
 
 
                                        
 
 
 Figure- 15 
 Effect of Atorvastatin and vitamin D3 on lipid profile in various 
patient population (N=60) 
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Table- 11 
 
t-test Results comparing Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile (at the end of 6th month) in various patient 
population 
 
Lipid profile Atorvastatin and 
vitaminD3(N=60) 
Atorvastatin   
(N=60) 
t test df 
Mean SD Mean SD 
Total 
cholesterol 
169.32 10.772 199.62 18.302 11.052 118 
LDL 98.20 9.176 123.78 14.330 11.642 100 
HDL 45.32 2.943 44.28 2.805 -1.969 118 
TG 129.57 35.999 165.23 44.577 4.821 113 
VLDL 25.80 7.189 32.71 9.022 4.641 112 
P<0.05 
 
              In order to compare the effect of Atorvastatin and vitamin D3 
combination with Atorvastatin on lipid profile in various patient populations 
an independent-samples t-test was conducted. 
1. The test indicated that serum total cholesterol levels were significantly 
lower for patients on atorvastatin and vit D3 (M = 169.32, SD = 10.772) 
than patients on atorvastatin (M = 199.62, SD = 18.302), t (96) = 11.05, 
 p < .001. Levene’s test indicated unequal variances (F = 19.35, p = .0001), 
so degrees of freedom were adjusted from 118 to 95.  
2.  The test indicated that serum LDL levels were significantly lower for 
patients on atorvastatin and vit D3 (M =98.20, SD =9.176) than patients on 
atorvastatin (M =123.78, SD =14.330), t (100) = 11.64, p < .001. Levene’s 
test indicated unequal variances (F = 14.13, p = .0001), so degrees of 
freedom were adjusted from 100-118. 
3.  The test indicated that serum HDL levels were significantly higher for 
patients on atorvastatin and vit D3 (M =45.32, SD =2.943) than patients on 
atorvastatin (M =44.28, SD =2.805), t (118) = -1.96, p < .001.  
4.  The test indicated that serum TG levels were significantly lower for 
patients on atorvastatin and vit D3 (M =129.57, SD =35.99) than patients on 
atorvastatin (M =165.23, SD =44.57), t (113) = 4.821, p < .001. Levene’s 
test indicated unequal variances (F = 4.75, p = .0001), so degrees of 
freedom were adjusted from 113-118. 
5.  The test indicated that serum VLDL levels were significantly lower for 
patients on atorvastatin and vit D3 (M =25.80, SD =7.18) than patients on 
atorvastatin (M =32.71, SD =9.022), t (112) = 4.64, p < .001. Levene’s test 
indicated unequal variances (F =5.29, p = .0001), so degrees of freedom 
were adjusted from 112-118. 
 Figure- 16 
     Comparing Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile (at the end of 6th month) in various patient 
population 
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Table- 12   
t-test Results comparing Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile in Hypertensive patients 
 
Lipid profile Atorvastatin and 
vitaminD3(N=30) 
Atorvastatin   
(N=30) 
t test df 
Mean SD Mean SD 
Total 
cholesterol 
164.10 9.484 188.17 10.175 9.477 58 
LDL 96.87 10.143 115.10 11.839 6.406 58 
HDL 47.60 2.191 46.70 1.557 -1.834 53 
TG 99.33 19.286 135.20 39.660 4.451 42 
VLDL 19.63 3.409 26.37 7.636 4.410 40 
 P<0.05 
               In order to compare the effect of Atorvastatin and vitamin D3 
combination with Atorvastatin on lipid profile in Hypertensive patients an 
independent-samples t-test was conducted. 
1. The test indicated that serum total cholesterol levels were significantly 
lower for patients on atorvastatin and vit D3 (M =164.10, SD=9.484) than 
patients on atorvastatin (M = 188.17, SD = 10.175), t (58) =9.47, p < .001 
 2.  Serum LDL levels were significantly lower for patients on atorvastatin 
and vit D3 (M =96.87, SD =10.143) than patients on atorvastatin (M 
=115.10, SD =11.839), t (58) = 6.406, p < .001.  
3.   Serum HDL levels were significantly higher for patients on atorvastatin 
and vit D3 (M =47.60, SD =2.191) than patients on atorvastatin (M =46.70, 
SD =1.557), t (53) = -1.83, p < .001. Levene’s test indicated unequal 
variances (F =4.653, p = .0001), so degrees of freedom were adjusted from 
52.3-58 
4.  Serum TG levels were significantly lower for patients on atorvastatin and 
vit D3 (M =99.33, SD =19.286) than patients on atorvastatin (M =135.20, 
SD =39.660), t (42) = 4.451, p < .001. Levene’s test indicated unequal 
variances (F = 10.06, p = .0001), so degrees of freedom were adjusted from 
41.9-58. 
5.  Serum VLDL levels were significantly lower for patients on atorvastatin 
and vit D3 (M =19.63, SD =3.409) than patients on atorvastatin (M =26.37, 
SD =7.636), t (40) = 4.41, p < .001. Levene’s test indicated unequavariances 
(F =8.52, p = .0001), so degrees of freedom were adjusted from 40.1-58.  
  
Figure- 17 
Comparing Atorvastatin and vitamin D3 combination with    
Atorvastatin on lipid profile in Hypertensive patients 
                             
 
 
 
 
 
0
20
40
60
80
100
120
140
160
180
200
Mean TC Mean LDL Mean HDL Mean TG Mean VLDL
164.1 
96.87 
47.6 
99.33 
19.63 
188.17 
115.1 
46.7 
135.2 
26.37 
atorvaD3
atorva
Table-13 
t-test Results comparing Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile in Chronic Kidney Disease  patients 
 
Lipid profile Atorvastatin and 
vitamin D3 (N=30) 
Atorvastatin   
(N=30) 
t test df 
Mean SD Mean SD 
Total 
cholesterol 
174.54 9.472 211.07 17.509 10.052 58 
LDL 99.53 8.046 132.45 11.043 13.196 58 
HDL 43.03 1.426 41.87 1.224 -3.400 58 
TG 159.80 19.324 195.26 24.517 6.221 58 
VLDL 31.96 3.865 39.05 4.906 6.218 58 
    P<0.05 
In order to compare the effect of Atorvastatin and vitamin D3 combination 
with Atorvastatin on lipid profile in patients  with Chronic Kidney Disease  
an independent-samples t-test was conducted. 
1. The test indicated that serum total cholesterol levels were significantly 
lower for patients on atorvastatin and vit D3 (M =174.54, SD=9.472) than 
patients on atorvastatin (M =211.07, SD =17.509), t (58) =10.052, 
p<.001.Levene’s test indicated unequal variances (F =2.953, p = .001), so 
degrees of freedom were adjusted from 44.6-58 
  2.  Serum LDL levels were significantly lower for patients on atorvastatin 
and vit D3 (M =99.53, SD =8.046) than patients on atorvastatin (M =132.45, 
SD =11.043), t (58) = 13.196, p < .001.  Levene’s test indicated unequal 
variances (F =1.898, p = .001), so degrees of freedom were adjusted from 
53-58. 
3.   Serum HDL levels were significantly higher for patients on atorvastatin 
and vit D3 (M =43.03, SD =1.426) than patients on atorvastatin (M =41.87, 
SD =1.224), t (58) = -3.400, p < .001.  Levene’s test indicated unequal 
variances (F =0.415, p = .0001), so degrees of freedom were adjusted from 
56.7-58 
4.  Serum TG levels were significantly lower for patients on atorvastatin and 
vit D3 (M =159.80, SD 19.324=) than patients on atorvastatin (M =195.26, 
SD =24.517), t (58) = 6.221, p < .001. Levene’s test indicated unequal 
variances (F = 2.915, p = .0001), so degrees of freedom were adjusted from  
54.9-58. 
5.  Serum VLDL levels were significantly lower for patients on atorvastatin 
and vit D3 (M =31.96, SD =3.865) than patients on atorvastatin (M =39.05, 
SD =4.906), t (58) = 6.218, p < .001. Levene’s test indicated unequal 
variances (F =2.925, p = .0001), so degrees of freedom were adjusted from 
54.9-58. 
 
Figure- 18 
Comparing Atorvastatin and vitamin D3 combination with 
Atorvastatin on lipid profile in Chronic Kidney Disease patients 
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DISCUSSION 
 
                                     
DISCUSSION 
 
          Dyslipidemia is an important predictor of cardiovascular disease.   
Dyslipidemia represents the elevation of plasma cholesterol and /or 
triglycerides or a low level of HDL. Multiple genetic abnormalities and 
environmental factors are involved in clinical lipid abnormalities and 
routinely used laboratory measurements do not define the underlying 
abnormalities. 
            Most patients with Dyslipidemia are asymptomatic for many years. 
It can be diagnosed on the basis of measurement of fasting lipid profile. 
            Initial therapy for Dyslipidemia is therapeutic life style changes with 
restricted intake of total and saturated fat along with regular physical 
activity. This is followed by pharmacological therapy. Lipid lowering drugs 
should be selected on the basis of specific lipoprotein disorder and plasma 
concentration of each lipoprotein.  
      Statins are the most potent and effective drug for the treatment of 
Dyslipidemia. Statins are the drug of choice for the management of 
Dyslipidemia because of their proven efficacy and safety profile. They also 
have a role in managing cardiovascular risk in patients with relatively 
normal levels of plasma cholesterol. They are highly efficacious at lowering 
LDL-C, with reduction ranges from 20%- 55% 49. Atorvastatin acts by 
inhibiting HMG-CoA redutase enzyme which is the rate limiting step for 
cholesterol biosynthesis. 
          Vitamin D3 has favorable effects on plasma lipid profile. It has TG 
lowering effects especially in patients with CKD. Two mechanisms have 
been proposed for TG lowering effect of vitamin D. First, vitamin D may 
reduce serum TG by reducing hepatic TG formation and secretion via an 
effect on hepatocellular calcium. Second, vitamin D has suppressive effect 
on serum parathyroid hormone (PTH) levels. The reduction in serum PTH 
may decrease serum TG via increased peripheral removal. It also has 
pleiotropic effect. Many physicians have increased their recommendations 
for vitamin D3 supplementation to at least 1000IU. Meta analytical studies 
from various sites have substantiated that supplementation with vitamin D 
has markedly reduced the mortality.   
        Statin and vitamin D have synergistic actions in preventing CVD. 
Addition of vitamin D3 improved statin tolerance by reducing the incidence 
of myalgia. Hence the study was undertaken to explore the effects of 
atorvastatin vitamin D3 combination on lipid profile in various patient 
population. 
     After the institutional ethical clearance and informed consent, a single 
blind open label, comparative trial was attempted among 120 patients with 
Dyslipidaemia. 
       120 patients with Dyslipidaemia were selected from outpatient 
department of general medicine and Nephrology. Their socio demographic, 
clinical and lab data were collected. They were explained about the study 
and were given the drugs orally. 
          Fasting plasma lipid profile, liver function tests were done before 
starting drug therapy. Treatment efficacy in both groups was assessed at the 
end of third and sixth month.  
                At the end of sixth month the mean total cholesterol was 
significantly reduced in atorvastatin vitamin D3 group than in atorvastatin 
group with ‘p’ value <0.001. The mean LDL-C, TG, VLDL were 
significantly reduced in atorvastatin vitamin D3 group than in atorvastatin 
group with ‘p’ value <0.001. The mean HDL-C in atorvastatin vitamin D3 
group was- 45.32 and in atorvastatin group was-44.28 with ‘p’ value 
<0.001. The significant reduction in total cholesterol, TG, LDL, VLDL 
could be due to reduction in hepatic TG formation and suppressive effect on 
parathyroid hormone levels. 
 
       Fasting plasma lipid profile improved significantly in both groups. 
However the improvement was very high in the atorvastatin vitamin D3 
group and also Myalgia was less common in atorvastatin vitaminD3 treated 
group compared to atorvastatin treated group12. 
      JB Schwartz, division of Clinical pharmacology, Department of 
Medicine, University of California, San Francisco, California, USA. showed 
that atorvastatin and vitaminD3 have synergistic effects on cholesterol 
concentration. 
       Ahmed et al, from the cholesterol center, Jewish hospital of Cincinnati, 
Cincinnati, Ohio showed that vitamin D3 improved statin tolerance by 
reducing myalgia. 
 
 
 
 
 
 
 
 
 
 
                                         
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
        SUMMARY 
              & 
      CONCLUSION 
 
                                   Conclusion and summary  
              Dyslipidaemia is associated with disturbance in lipoprotein 
metabolism. Elevated LDL and low HDL are unequivocally linked to 
increased risk for cardiovascular and cerebrovascular morbidity and 
mortality. LDL is the primary target. Reduction in total cholesterol and 
LDL-C with increase in HDL-C will   reduce the cardiac events. More than 
half of individuals at borderline risk remain unaware that they have 
Dyslipidaemia. Unfortunately, the identification of patients at high risk 
because of Dyslipidemia is too frequently overlooked, because blood lipid 
levels are not always evaluated, even after an event such as Myocardial 
infarction. 
     120 patients with Dyslipidaemia were selected from outpatient 
department of general medicine and Nephrology. Out of 120 patients, 60 
patients were treated with atorvastatin 10 mg/day orally and the remaining 
60 patients were treated with atorvastatin 10mg and vitamin D3 1000IU/day 
orally. 
Both groups were followed for a period of 6 months. The compliance was 
checked and efficacy was monitored by doing lipid profile. 
The Atorvastatin and vitamin D3 treated group showed good response 
compared to atorvastatin treated group. 
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ANNEXURES 
 
 
 
 
 
 
 
                                                 PROFORMA 
             
Name        OP/IP No. 
Age  
Sex 
Occupation 
Address 
Socio economic status 
Phone no. 
H/o presenting illness : 
Past history : 
H/o Comorbid Illness. 
Family h/o: 
Occupational H/o: 
Menstrual history:  
Personnel History: 
H/o Smoking 
H/o alcoholism. 
Dietary Habits. 
Treatment History : 
Drug History 
H/O about drug compliance: 
H/O  any adverse Effect to drugs: 
General examination 
HEIGHT:                     WEIGHT:                          BMI:                        
O/E 
Conscious 
Oriented 
Pallor  
Cyanosis 
Clubbing 
Pedal edema 
Generalized lymphadenopathy 
VITALS 
Pulse : 
B.P 
R.R 
Temp 
Examination of neck :  
Any Carotid Bruit, Elevated JVP, Any signs of Thyroid swelling, 
Skin examination       :  
Face  
CVS 
RS 
P/A 
CNS 
 
 
Investigations 
Baseline Investigations 
Complete hemogram 
Liver function tests 
Bilirubin (total,direct,indirect), SGOT, SGPT, Total Proteins, Albumin, 
Globulin. 
Lipid Profile 
Parameter      Baseline 3 Months 6 Months 
Total Cholesterol    
VLDL    
LDL    
HDL    
TG    
 
 
 
 
 
 
 
 
 
 
 
 
                  INFORMED CONSENT FORM IN ENGLISH 
 
Full name of the patient(in capital letters):   __________________________          
Address:______________________________________________________   
__________________________________Date of Birth:______________       
Patient no:_____________  Sex :________    I  freely  agree  to  participate  
in  the above – mentioned clinical study. 
My doctor_____________________ informed me in a personal counseling 
interview about the study drug, possible side effects and risks, the nature, 
objective and significance  of  this  clinical  study  and  my  responsibilities  
resulting  thereof.  In addition,  I  read  and  understood  the  contents  of  
the  Patient  Information  Sheet and Informed Consent Form. The doctor 
answered all questions in an adequate and comprehensible manner. I had 
sufficient time to decide on my participation in  this  clinical  study.   
I  will  follow  the  instruction  of  my  doctor,  which  are essential for the 
performance of this clinical study. I have the right to withdraw from  the  
study  at  any  time  without  giving  any  reason  and  without  any 
disadvantage for me.I confirm that I have not participated in this study and I 
have not taken  part in another study within the last 30 days prior to the start 
of the study. 
I received one original of the Patient Information Sheet together with the 
signed Information Consent Form. 
_____________________________________________________________ 
( Place, Date & Signature of the Patient) 
_____________________________________________________________ 
( Place, Date & Signature of the Doctor) 
 
                               PATIENT INFORMATION SHEET 
Who can be contacted for further questions? 
 
For further questions regarding this clinical study or your rights as patient 
and participant in the study, please contact your doctor who will always be 
ready to provide you the necessary information. 
 
If you have experienced any health related problems as well as in case of 
hospitalization please contact your doctor. 
Name and Address of the Contact Person:  
_____________________________________________________________ 
_____________________________________________________________ 
Phone number: ________________________________________________                   
 
          Please take a copy of this information sheet home with you. 
 
          
ப்வேு ேகை வ ோயோளிைளி் ர்தகைோு்ு அளேிகை 
அ்டோ்ேோ்டோ்ி்  ம்ு் ேி்டமி் ி 3 கய 
அ்டோ்ேோ்டோ்ி்  உட் ஒ்பீ்ு ஆ்ு.  
ந ோயோளி  அடையோள்பு்ுத்  : 
ப்நே்போள்  எ்  : 
ஒு ஆரோ்்சி ஆ்வி்  ப்நே்ு்பி  ீ்ே் 
நே்ு்கேோ்ள்புேிறீ் ே்.ப்ு கபற உ்ேு்ு விு்பமோ 
,எ்படத  ுிு கச்ய உ்ேு்ு உதவ இ்த்பிவ் 
தேவ்ேடள் கேோ்ு்ளு.ந ர் எு்ு்கேோ்ு ,இ்த 
பிவ்டத ேவனமோே பி்ு உ்ேு்ு இு்ு் ஐய்போுேடள 
ஆ்ு மு்ுவடரநயோ அ்லு ஏுு் ஊழிய்ேடளநயோ 
நே்ேு். 
இ்த ஆ்கே ப்றி :- 
இர்த்தி் கேோு்ு அதிேமோே  இு்பவ்ேு்ு இர்த்தி் 
கேோு்ு அளடவ் ுடற்ே அ்ைோ்வோ்ைோ்ி் ம்ு் 
வி்ைமி் ி 3 டய அ்ைோ்வோ்ைோ்ி் உை் ஒ்பீ் ு ஆ்ு. 
இ்த ஆ்வி் ப்நே்ே  ீ்ே் அுமதி்ே்புவத்ு இ்த 
ேோரண்ே் இு்ே்ூு் .உ்ேு்ு இர்த்தி் கேோு்ு 
அதிேமோேஇு்பதினோ். ோ் எ்ை கெ்ுமோு 
வை்ுகைோ்ள்புவே் . 
 சோ்பிு்நபோு உ்ு ுடறவோேநவோ அ்லு ு்றிுமோே உ்ு 
நச்்ேோமநலோ இு்பு. 
இர்ு வோர்தி்ு ஒு ுடற வ்ு மோ்திடரேடள 
வோ்ேி்கேோ்வு . 
ுடறயோே  உை்பயி்சி கச்வு. 
ந ர்தி்ு சியோே ு்ுவு. 
மு்ுவ் அறிுடர இ்லோம் எ்த ஒு ுதிய மு்நதோ 
மோ்திடரநயோ உ்கேோ்ளோம் இு்பு .  
 ீ்ே் ஒ்கவோு ுடற வு்கபோுு்  ீ்ே் எு்தமு்தி் 
ேோலிஅ்டைேடள கேோ்ுவுவு . 
வுடேயி் இடையி் உ்ேு்ு ஏநது் ப்ேவிடளுே் 
இு்ேிறதோ எ்படத அறி்ு கேோ்வத்ேோே, ஆ்ு 
ஊழிய்ேளிைமிு்ு வு் கதோடலநபசி அடழ்ுேடள 
கப்ுகேோ்வு.  
 ீ்ை் உ்ை் ஆ்ு ேுகைைு்ு ேு்வபோு ஆ்ு 
மு்ுேரோ் அ்லு ஆ்ு ஊழிய்ைளோ் 
பி்ேுபகேைளி் ஏுு் ஒ்வறோ இ்கல 
ுுேுமோைவேோ உ்பு்தபுே ீ் ை். 
உ்ே் மு்ுவ வரலோ்டற முஆ்ு கச்வு. 
ஆ்ு மு்ுேடளு் அறிுடரேடளு் வழ்ுவு. 
உ்ேளு இதய்ுி்ு ,இர்தஅு்த் ,உை்எடை,உயர் 
,வயி்றி் ு்றளு, ஆேியவ்டற அள்பு . 
இர்த் ம்ு் சிு ீ் மோதி ே் பிநசோதடன. 
எகல்்நரோ ேோ்ிநயோ்ரோ் ( இுதய ுு் பை்). 
மு்ுை் எ்கபோுதோேு ைீ்்ை்ட பி்ேிகளுைகளவயோ 
அ்லு ப்ைேிகளுைகளவயோ உ்டோ்ைலோ். 
வோ்தி, மு்ு ஒ்வோடம, . 
டே ேோ் தடச வலி. 
ஆ்வி் நபோு பி்விடளுே் ஏ்்ப்ைோ் ஆ்ு மு்ு 
உ்கேோ்வடத  ிு்திவி்ு உைனியோே மு்ுவடர 
அுேநவ்ு்.உ்ே் மு்ுவ் நவு மு்ு கேோு்ு 
பி்விடளுேடள  ிு்த ுய்சி்போ். 
இர்த் பிவெோதகை கெ்ேதோ் உ்டோு் எதி்ேிகளுை் 
 கபு்போலோனவ்ேு்ு இர்த் எு்பத்ேோே ஊசி 
ு்ுவு எ்வித நமோசமோன பிர்சடனேடளு் 
ஏ்பு்ுவதி்டல.ஆயிு் , சில ந ர்ேளி் இர்த் 
எு்ே்ப்ை இை்தி் , இர்த் ேசிு , இர்த் ே்றி் நபோத் 
,அகசௌேிய் , ந ோ்கதோ்ு்ே் ம்ு் /அ்லு வலி 
ஆேியடவ உ்ைோேலோ்.  ீ்ே் தடலு்ுவதோேு் உணரலோ் 
எல்வரோைோ்ிவயோ்ரோ் / ஈ . ெி . ஜி 
  எல்நரோேோ்ிநயோ்ரோ் / ஈசிஜி பிநசோதடன 
இதய்ுி்ு அ்லு இதய தோள்தி் மி்சோர தைமறித்.அடவ 
ஈநேஜி பிநசோதடன எனு் அடழ்ேபுேி்றன. ஈசிஜி 
பிநசோதடன கச்ு கேோ்வத்ு , உ்ே் உைலி் ப்நவு 
புதிேளி் ஒ்ு்ே் டவ்ே்பு். 
உலைளோேிய தருை் போுைோ்ு அறி்கை 
 இ்த ஆ்டவ  ை்ுவத் ஒு புதியோே ,உ்ே் 
மு்ுவ் தேவ்ேடள ஆ்ு மு்ுவ் தவிர பிறுை் 
பேி்்ு கேோ்வு அவசியமோேிறு .உ்ே் தனி்ப்ை 
ஆநரோ்ேிய் தேவ்ே் எ்வோு பய்பு்த்பு் ம்ு் இ்த 
ஆரோ்்சி ஆ்ு்ேோே அடவ யோு்ு் தர்பு் 
(கவளி்பு்ுத்) எ்படவ ப்றி , தருே் போுேோ்ு அறி்டே 
விள்ேமளி்ேிறு. உ்ே் தனி்ப்ை ஆநரோ்ேிய் 
தேவ்ேடள் போ்டவயிை உ்ே் உிடமே் உ்பை உ்ேளு 
போுேோ்ு உிடமேடளு் இு விவி்ேிறு. 
  ீ்ே் யோ் எ்ு ே்ைறிய் பய்பு்தபு் 
உ்ேடள் ப்றிய தேவ்ேநள உ்ே் தனி்ப்ை ஆநரோ்ேிய் 
தேவ்ேளோு். இ்த ஆ்வி்ு் நதடவ்பு் த்நபோடதய 
உ்ே் மு்ுவ் பதிநவுேளி் உ்ள தேவ்ே் இ்த 
ஆ்வி்நபோு உுவோ்ே்பு் அ்லு நசேி்ே்பு் ுதிய 
தேவ்ே் ஆேியவ்டற உ்ளை்ேியடவநய இ்த ஆ்வி்ு் 
நதடவயோன தேவ்ேளோு். 
 இ்த ஆ்வி்ேோன ஒ்ுத் பிவ்தி் 
டேகயோ்பமிுவத் வோயிலோே , இ்த தருே் போுேோ்ு 
அறி்டேயி் விவி்ே்ப்ு்ள உ்ே் தனி்ப்ை 
ஆநரோ்ேிய் தேவ்ேடள பய்போ்ு்ு் 
கவளி்பு்ுது்ு்  ீ்ே் அுமதி (“அ்ேீேோர் “) 
அளி்ேிறீ் ே் . இ்பய்போுேடள  ீ்ே் அுமதி்ே 
விு்பவி்டல எ்றோ், இ்த ஆ்வி்  ீ்ே் ப்நே்ே் 
ூைோு. 
 இ்த ஆ்வி் ப்நே்ே  ீ்ே் ஒ்ு் கேோ்ைோ், 
உ்ே் தனி்ப்ை ஆநரோ்ேிய் தேவ்ே் ேீ்்ே்ை 
வழிேளி் பய்பு்த்பு் ம்ு் கவளி்பு்த்பு். 
 ஆ்வி் நபோு ,ஆ்டவ  ை்ுவத்ேோே , உ்ே் 
மு்ுவ் பதிநவுேடளு் ,உுவோ்ே்ப்ை அ்லு 
நசேி்ே்ப்ை தேவ்ேடளு் ஆ்ு மு்ுவ் ம்ு் 
ஊழிய்ே் பய்பு்ுவோ்ே். 
 ஒ்ுத் பிவ்தி் விவி்ே்ப்ை ஆ்வி் அறிவிய் 
ந ோ்ே்ேு்ு ஆதரவளி்ு் ஆரோ்்சி் 
ேோரண்ேு்ேோேு் ,ஆ்வி் நச்்ே்ப்ை மு்ு 
அ்லு சிேி்டசயி் போுேோ்ு ம்ு் பல்ேடள 
மதி்புீ கச்யு் , ஆ்வி் நச்்ே்ப்ு்ள 
ந ோ்(ே்) ப்றி சிற்போே ுி்ு கேோ்ளு் அ்லு 
எதி்ேோல ஆ்ுேடள விவடம்ு நம்பு்து் இ்த 
ஆ்ு் தருே் பய்பு். 
 உ்ேடள அடையோள் ேோணோத ஆ்ு் தருே் 
மு்ுவ இத்ேளி் கவளியிை்பைலோ் அ்லு 
அறிவிய் விவோத்ேளி் ஒு புதியோே ம்றவ்ேுை் 
பேி்்ு கேோ்ள்பைலோ். 
 உ்ே் மு்ுவ பதிநவுே் ம்ு் ஆ்ு் தருே் 
ேணினிேளி் டவ்ே்ப்ு கசய்ுடற்பு்த்பைலோ். 
 ஆ்ு கதோை்போன உ்ே் தனி்ப்ை ஆநரோ்ேிய் தேவ்ே் 
,ஆ்ு மு்ுவிை் இு்ு்வடர ,அவ்டற  ீ்ே் 
போ்டவயிைு் அவ்றி்  ேடல் கபறு் ,உ்ேு்ு 
உிடமு்ு. இு்பிு் ,ஆ்வி் அறிவிய் 
ஒுடம்போ்டை உுதிகச்ு் கபோு்ு,ஆ்ு ுிவடைு் 
வடர சில ஆ்ு் தேவ்ேடள  ீ்ே் முஆ்ு கச்ய 
ுியோு. 
 ஆ்ு மு்ுவு்ு எு்ு ூல் அறிவி்டப அளி்ு 
உ்ே் அ்ேீேோர்டத எ்நபோு நவ்ுமோனோு்  ீ்ேி விைலோ். 
 ீ்ே் உ்ே் அ்ேீேோர்டத  ீ்ேி் கேோ்ைோ் ,ஆ்வி் 
அறிவிய் ஒுடம்போ்டை போுேோ்பத்ேோே , ஆ்ு மு்ுவ் 
அ்லு ஊழிய்ே் இ்த ஆ்ுை் கதோை்ுடைய உ்ே் 
தனி்ப்ை மு்ுவ் தேவ்ே் சிலவ்டற பய்பு்ு் 
அ்லு உிடம வழ்ே் நதடவ இ்லோதவடர , உ்ே் ஆ்ு 
மு்ுவ் அ்லு ஊழிய்ே் உ்ே் தனி்ப்ை ஆநரோ்ேிய் 
தேவ்ேடள் பய்பு்தநவோ அ்லு கவளி்பு்தநவோ 
மோ்ைோ்ே்.  
வ ோயோளி தைே் ம்ு் ஒ்ுத் பிே் இகை்ு 2 
ஆ்ேிட் தைே் ம்ு் கதோட்ு ேிேர்ை். 
கவ்நவு வடே ந ோயோளி ம்ேளி் அ்ைோ்வோ்ைோ்ி் 
ம்ு் வி்ைமி் ி 3 டய அ்ைோ்வோ்ைோ்ி் உை் ஒ்பீ் ு 
ஆ்ு. 
ஆ்ு ுறி்த ஐய்போுை் ம்ு்  ேிேர்ைகள் ப்றி 
வை்பத்ைோை ஆ்ு மு்ுே்ைளி் கதோட்ு ேிேர்ை். 
ஆ்ு மு்ுேி் கபய்      . 
ுேவி                             . 
கதோை்ு எ்                  
ஓ் ப்வை்போளரோை உ்ை் உிகமைகள் ப்றி 
வை்பத்ைோை ஈஆ்பி கதோட்ு ேிேர்ை் 
ஐஆ்பி கதோட்ு பி் கபய்                                         
கதோை்ுஎ்       
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1 39876 56 F 1.6 60 23.43 HT Atorva 233 166 41 130 26 193 123 46 120 24 
2 36543 48 M 1.54 58 24.47 HT Atorva 227 155 42 150 30 185 115 46 120 24 
3 76089 38 M 1.62 62 23.62 HT Atorva 218 135 40 215 43 165 100 45 100 20 
4 70014 39 M 1.48 60 27.39 HT Atorva 214 148 40 130 26 176 111 45 201 20 
5 65509 45 M 1.44 56 27 HT Atorva 215 145 40 150 30 174 110 44 100 20 
6 23409 52 F 1.61 58 22.37 HT Atorva 220 146 44 150 30 179 105 48 130 26 
7 33008 53 M 1.58 66 26.43 HT Atorva 235 168 40 135 27 197 128 46 115 23 
8 45076 57 F 1.52 65 28.13 HT Atorva 228 145 46 185 37 188 110 48 150 30 
9 34778 58 M 1.42 65 32.23 HT Atorva 216 144 40 160 32 184 110 46 140 28 
10 45787 48 F 1.66 68 24.67 HT Atorva 255 180 45 150 30 204 130 48 130 26 
11 56609 47 F 1.5 70 31.11 HT Atorva 220 160 40 140 28 196 124 48 120 24 
12 88700 49 F 1.4 75 38.26 HT Atorva 261 190 46 125 25 205 134 50 105 21 
13 680099 50 M 1.41 66 33.19 HT Atorva 240 178 40 110 22 190 126 46 90 18 
14 25564 60 M 1.35 69 37.86 HT Atorva 215 155 40 100 20 196 133 47 80 16 
15 35564 57 F 1.38 78 40.95 HT Atorva 241 166 45 150 30 185 112 48 125 25 
16 30657 48 M 1.7 66 22.83 HT Atorva 251 191 40 100 20 174 110 46 90 18 
17 47095 49 M 1.62 72 27.43 HT Atorva 220 150 40 150 30 201 130 46 125 25 
18 42006 48 F 1.58 80 32.04 HT Atorva 215 145 45 125 25 180 110 48 110 22 
19 50608 47 F 1.56 58 23.83 HT Atorva 258 185 45 140 28 207 135 49 115 23 
20 71123 48 M 1.57 62 25.15 HT Atorva 210 140 40 150 30 181 108 47 130 26 
21 57077 54 F 1.6 60 23.43 HT Atorva 224 146 44 170 34 182 109 45 140 28 
22 43007 53 F 1.6 60 23.43 HT Atorva 238 150 40 240 48 200 112 48 200 40 
23 54861 57 M 1.55 56 23.3 HT Atorva 210 110 45 275 55 182 90 44 240 48 
24 70098 47 F 1.58 67 26.83 HT Atorva 220 140 40 200 40 193 110 48 175 35 
25 55765 45 F 1.64 78 29 HT Atorva 233 160 45 140 28 195 125 46 120 24 
26 65007 54 M 1.68 84 29.76 HT Atorva 207 120 40 235 47 185 98 45 210 42 
27 54006 56 M 1.7 80 27.68 HT Atorva 228 156 40 160 32 185 114 45 130 26 
28 33765 55 M 1.8 64 19.75 HT Atorva 212 140 40 160 32 182 110 46 130 26 
29 65743 48 F 1.38 72 37.8 HT Atorva 241 168 45 140 28 195 125 48 110 22 
30 45588 49 F 1.44 70 33.75 HT Atorva 212 120 45 235 47 186 96 49 205 41 
31 11034 46 M 60 1.5 26.66 CKD Atorva 220 130 40 250 50 153 104 42 225 45 
32 14584 48 M 55 1.7 19.03 CKD Atorva 279 191 40 240 48 237 152.5 42 212.5 42.5 
33 10345 52 M 70 1.8 21.6 CKD Atorva 227 150 40 185 37 193 120 42 157.25 31.4 
34 13440 44 F 54 1.6 21.09 CKD Atorva 257 161 44 260 52 219 128.8 46 221 44.2 
35 11254 38 M 80 1.54 33.73 CKD Atorva 241 166 38 185 37 174 133 40 157 31.4 
36 14832 49 M 56 1.55 23.3 CKD Atorva 210 132 40 190 38 180 106 42 162 32.4 
37 18360 51 F 58 1.6 22.65 CKD Atorva 240 162 40 190 38 204 130 42 162 32.4 
38 11442 48 M 64 1.63 24.08 CKD Atorva 254.5 161.1 40.6 264 52.8 217 130 42 225 45 
39 11340 39 M 66 1.7 22.83 CKD Atorva 250.5 162.5 40 240 48 211 129 42 204 40.8 
40 11534 47 F 67 1.58 26.83 CKD Atorva 241.8 150.8 40 255 51 215.4 130 42 217 43.4 
41 12134 52 M 70 1.54 29.51 CKD Atorva 253.8 162.5 40.2 255.5 51.1 206.2 120.8 42 217 43.4 
42 13544 55 M 72 1.54 30.35 CKD Atorva 260.4 171.4 40 245 49 216 129 42 225 45 
43 13324 53 M 74 1.46 34.71 CKD Atorva 241.8 166.8 38 185 37 213 141.4 40 158 31.6 
44 10123 49 M 63 1.48 28.76 CKD Atorva 258.4 190.41 38 262 52.4 217.6 133 40 223 44.6 
45 10233 55 M 70 1.52 30.29 CKD Atorva 246.7 160.2 39 237.5 47.5 233.4 152 41 202 40.4 
46 12098 50 M 74 1.6 28.9 CKD Atorva 260 172 40 240 48 210.8 128 42 204 40.8 
47 13324 46 F 75 1.58 30.04 CKD Atorva 256 164 40 260 52 216 129 43 220 44 
48 14221 48 M 66 1.6 25.78 CKD Atorva 248 170 40 190 38 206.4 132 42 162 32.4 
49 11001 50 F 58 1.53 24.77 CKD Atorva 269 180 40 245 49 227.8 144 42 209 41.8 
50 11324 38 F 56 1.55 23.3 CKD Atorva 264 178 40 230 46 224.2 143 42 196 39.2 
51 11846 48 M 45 1.6 17.57 CKD Atorva 240 157 38 225 45 204.4 126 40 192 38.4 
52 23111 56 M 62 1.7 21.45 CKD Atorva 248 168 38 210 42 211.8 135 41 179 35.8 
53 11007 55 F 64 1.66 23.22 CKD Atorva 260 180 40 200 40 222 144 44 170 34 
54 13280 52 F 63 1.65 23.14 CKD Atorva 250 170 41 195 39 214 136 43 166 33.2 
55 14327 58 M 62 1.64 23.05 CKD Atorva 248 169 38 205 41 210 135 40 175 35 
56 13528 45 M 65 1.63 24.46 CKD Atorva 238 155 40 215 43 202.6 124 42 183 36.6 
57 11473 48 F 66 1.61 25.46 CKD Atorva 254 167 40 235 47 217 135 42 200 40 
58 17655 44 F 63 1.5 28 CKD Atorva 260 168 40 260 52 222 136 42 221 44.2 
59 11098 52 F 62 1.6 24.21 CKD Atorva 258 172 40 230 46 223.2 142 42 196 39.2 
60 11065 50 M 61 1.5 27.11 CKD Atorva 266 175 40 255 51 230.4 145 42 217 43.4 
61 22332 39 F 1.54 80 33.73 HT Atorva+vit D3 248 180 40 140 28 165 100 45 100 20 
62 54321 43 M 1.7 78 26.98 HT Atorva+vit D3 280 214 38 140 28 184 119 44 105 21 
63 35045 45 F 1.55 76 31.63 HT Atorva+vit D3 260 182 38 200 40 181 110 45 130 26 
64 28745 56 M 1.56 55 22.6 HT Atorva+vit D3 230 156 40 170 34 175 106 46 150 23 
65 29020 57 F 1.6 54 21.09 HT Atorva+vit D3 260 190 38 160 32 169 104 44 105 21 
66 53468 48 M 1.62 48 27.43 HT Atorva+vit D3 270 202 40 140 28 165 100 46 95 19 
67 48152 49 M 1.59 52 20.56 HT Atorva+vit D3 240 172 38 150 30 155 90 45 100 20 
68 39660 39 M 1.53 60 25.63 HT Atorva+vit D3 240 175 40 125 25 152 88 46 90 18 
69 53766 55 F 1.52 65 28.13 HT Atorva+vit D3 260 195 38 135 27 158 95 44 95 19 
70 48054 57 F 1.7 67 23.18 HT Atorva+vit D3 250 182 38 150 30 153 90 43 100 20 
71 36213 56 F 1.6 80 31.25 HT Atorva+vit D3 233 166 41 130 26 167 100 49 90 18 
72 35689 52 F 1.54 75 31.64 HT Atorva+vit D3 227 155 42 150 30 163 93 50 100 20 
73 86008 53 M 1.53 66 28.18 HT Atorva+vit D3 218 135 40 215 43 151 75 48 140 28 
74 83221 54 M 1.56 63 25.88 HT Atorva+vit D3 214 148 40 130 26 156 90 48 90 18 
75 78034 57 M 1.5 70 31.11 HT Atorva+vit D3 215 145 40 150 30 156 87 49 100 20 
76 51112 54 F 1.61 74 28.54 HT Atorva+vit D3 220 146 44 150 30 158 88 50 100 20 
77 43545 47 F 1.7 72 24.91 HT Atorva+vit D3 235 168 40 135 27 168 100 50 90 18 
78 58347 43 F 1.6 80 31.25 HT Atorva+vit D3 228 145 46 185 37 165 87 50 140 28 
79 38453 46 M 1.5 76 33.77 HT Atorva+vit D3 216 144 40 160 32 155 86 48 105 21 
80 20876 46 F 1.6 70 27.34 HT Atorva+vit D3 255 180 45 150 30 173 104 49 100 20 
81 30098 55 M 1.4 82 41.83 HT Atorva+vit D3 220 160 40 140 28 163 96 49 90 18 
82 45087 50 F 1.62 81 30.86 HT Atorva+vit D3 261 190 46 125 25 178 112 50 80 16 
83 34354 38 F 1.58 88 35.25 HT Atorva+vit D3 240 178 40 110 22 171 106 48 85 17 
84 87767 44 F 1.6 65 25.39 HT Atorva+vit D3 215 155 40 100 20 155 93 49 65 13 
85 76001 58 F 1.7 60 20.76 HT Atorva+vit D3 241 166 45 150 30 168 99 49 100 20 
86 46377 48 M 1.56 62 25.47 HT Atorva+vit D3 251 191 40 100 20 174 113 48 65 13 
87 65011 51 M 1.58 64 25.63 HT Atorva+vit D3 220 150 40 150 30 158 90 48 100 20 
88 34476 58 F 1.6 65 25.39 HT Atorva+vit D3 215 145 45 125 25 152 87 49 80 16 
89 30098 54 F 1.5 66 29.33 HT Atorva+vit D3 258 185 45 140 28 178 110 50 90 18 
90 26678 50 F 1.6 70 27.34 HT Atorva+vit D3 210 140 40 150 30 157 88 49 100 20 
91 11033 45 M 58 1.41 29.17 CKD Atorva+vit D3 240 157 38 225 45 170 95 44 158 31.6 
92 11543 48 M 65 1.44 31.34 CKD Atorva+vit D3 248 168 38 210 42 172.4 101 42 147 29.4 
93 10365 57 F 59 1.5 26.22 CKD Atorva+vit D3 260 180 40 200 40 179 108 43 140 28 
94 13442 54 F 70 1.6 27.34 CKD Atorva+vit D3 250 170 41 195 39 172.4 102 43 137 27.4 
95 11235 52 M 72 1.52 31.16 CKD Atorva+vit D3 248 169 38 205 41 170.8 102 40 144 28.8 
96 11453 60 M 80 1.6 31.25 CKD Atorva+vit D3 238 155 40 215 43 167.2 93 44 151 30.2 
97 14382 47 M 62 1.7 21.45 CKD Atorva+vit D3 254 167 40 235 47 177 101 43 165 33 
98 18630 49 M 63 1.6 24.6 CKD Atorva+vit D3 260 168 40 260 52 181.4 101 44 182 36.4 
99 14142 46 M 71 1.5 31.55 CKD Atorva+vit D3 258 172 40 230 46 180.2 104 44 161 32.2 
100 12131 38 M 72 1.54 30.35 CKD Atorva+vit D3 266 175 40 255 51 184.8 105 44 179 35.8 
101 10055 39 M 76 1.52 32.89 CKD Atorva+vit D3 220 130 40 250 50 156 78 43 175 35 
102 14322 48 M 66 1.6 25.78 CKD Atorva+vit D3 279 191 40 240 48 191.6 115 43 168 33.6 
103 10978 44 M 64 1.56 26.29 CKD Atorva+vit D3 227 150 40 185 37 159 90 43 130 26 
104 12003 36 F 63 1.58 25.23 CKD Atorva+vit D3 257 161 44 260 52 180.4 97 47 182 36.4 
105 13426 48 M 58 1.5 25.77 CKD Atorva+vit D3 241 166 38 185 37 168 100 42 130 26 
106 11968 53 M 60 1.5 26.66 CKD Atorva+vit D3 210 132 40 190 38 150.6 80 44 133 26.6 
107 10654 52 M 54 1.6 21.09 CKD Atorva+vit D3 240 162 40 190 38 167.6 98 43 133 26.6 
108 12341 48 F 60 1.7 20.76 CKD Atorva+vit D3 254.5 161.1 40.6 264 52.8 177 97 43 185 37 
109 10342 47 M 48 1.58 19.22 CKD Atorva+vit D3 250.5 162.5 40 240 48 174.6 98 43 168 33.6 
110 14432 45 M 58 1.6 22.65 CKD Atorva+vit D3 241.8 150.8 40 255 51 169.8 90 44 179 35.8 
111 16243 56 F 55 1.52 23.8 CKD Atorva+vit D3 253.8 162.5 40.2 255.5 51.1 176.8 98 43 179 35.8 
112 15332 54 M 56 1.6 21.87 CKD Atorva+vit D3 260.4 171.4 40 245 49 181.4 103 43 172 34.4 
113 11398 55 M 74 1.48 33.78 CKD Atorva+vit D3 241.8 166.8 38 185 37 167 100 41 130 26 
114 11324 54 M 63 1.5 28 CKD Atorva+vit D3 258.4 190.41 38 262 52.4 190.8 114 40 184 36.8 
115 10067 43 M 60 1.51 26.31 CKD Atorva+vit D3 246.7 160.2 39 237.5 47.5 169.2 96 40 166 33.2 
116 13328 46 M 72 1.6 28.12 CKD Atorva+vit D3 260 172 40 240 48 181.6 104 44 168 33.6 
117 15422 48 F 56 1.45 26.63 CKD Atorva+vit D3 256 164 40 260 52 178.4 99 43 182 36.4 
118 10303 50 M 58 1.5 25.77 CKD Atorva+vit D3 248 170 40 190 38 171.6 102 43 133 26.6 
119 11748 46 F 54 1.4 27.55 CKD Atorva+vit D3 269 180 40 245 49 186.4 108 44 172 34.4 
120 10568 44 M 55 1.4 28.06 CKD Atorva+vit D3 264 178 40 230 46 183.2 107 44 161 32.2 
 
 ABBREVIATIONS 
 
ABC- ATP-binding cassette 
ACAT- Acyl coenzyme A: Cholesterol acyl transferase 
ALT- alanine transaminase 
ATP- Adult Treatment Panel 
CAD- Coronary Artery Disease 
CETP- cholesterol ester transfer protein 
CK- creatine  kinase 
CRP- C-reactive protein 
CVD- Cardio Vascular Disease 
CYP- Cytochrome P 
DM- Diabetes Mellitus 
FFA- Free fatty acid 
HDL- High Density Lipoproteins 
HL-Hepatic lipase 
HMG- CoA- 3-Hydroxy-3methyl glutaryl coenzyme A 
IDL- Intermediate Density Lipoproteins 
IL- interleukin 
LCAT- lecithin cholesterol acyl transferase 
LDL- Low Density Lipoproteins 
LP (a)- Lipoprotein (a) 
LPL- Lipoprotein lipase 
LRP- LDL receptor-related protein 
MTP- Microsomal triglyceride transfer protein 
NCEP- National Cholesterol Education Program 
OATP- organic anion- transporting polypeptide 
PTH- parathyroid hormone 
RNA- Ribonucleic acid 
Scap- SREBP and its cleavage activating protein 
SR- Scavenger receptor 
SREBP- sterol regulatory element binding proteins 
TG- Triglycerides 
TNF- tumor necrosis factor 
UVB- Ultraviolet-B 
VLDL- Very Low Density Lipoproteins 
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